(HNSN) Enters Into Agreement With Investors to Receive up to $93 Million in Equity Financing

Company to Receive Upfront $39 Million Upon Closing

Hansen Medical Enters Into Agreement With Investors to Receive up to $93 Million in Equity Financing

Company to Receive Upfront $39 Million Upon Closing

(EHTH) Federal Government Signs Web-Broker Entity Agreement With eHealth

Paves the Way for eHealth to Help Enroll Uninsured Subsidy-Eligible Individuals in 36 States; eHealth CEO Gary Lauer Says: “We Now Hope That the 14 Remaining States Will Follow the Leadership of the Federal Government and Allow Their Subsidy-Eligible Residents the Same Opportunity”

Federal Government Signs Web-Broker Entity Agreement With eHealth

Paves the Way for eHealth to Help Enroll Uninsured Subsidy-Eligible Individuals in 36 States; eHealth CEO Gary Lauer Says: “We Now Hope That the 14 Remaining States Will Follow the Leadership of the Federal Government and Allow Their Subsidy-Eligible Residents the Same Opportunity”

(MGAM) Q3 Revenue Up 19%, New Quarterly Record of $48.1M

Multimedia Games Holding Company, Inc. (Nasdaq: MGAM) (“Multimedia Games” or the “Company”) today reported operating results for its fiscal 2013 third quarter ended June 30, 2013, as summarized below:

Patrick Ramsey, President and Chief Executive Officer of Multimedia Games, commented, “Our record quarterly revenue and overall strong financial performance reflects our ongoing success in creating great games that resonate with customers. We continue to expand the Company’s total addressable market while simultaneously achieving growth in existing markets. We delivered quarterly revenue of over $48 million as we deployed over 1,000 new revenue units for the fourth consecutive quarter, with products placed in 21 states, and generated operating margins that continue to be at the high end of our industry peer group, coming in at 29.1% of revenues. Combined, these factors enabled us to generate $14 million in free cash flow (definition provided below). Further, the operating leverage in our business was evident in the quarter as EBITDA growth of 30% outpaced the approximately 19% increase in revenue.

“During the quarter we further expanded our addressable markets as Nevada sales and placements began in earnest and we generated our first sales in New Jersey. Our MForce™ gaming platform completed additional Nevada technical field trials, allowing us to address the majority of the potential customers in the state. In addition, we have expanded our portfolio of approved games in Nevada to 22 titles, including TournEvent®, which received final approvals late in the fiscal third quarter. During the fiscal 2013 third quarter, we sold or placed 102 games in Nevada and we expect to continue our penetration into this important market.

“Gaming operations growth also continued as we added 451 net new units to the installed base, including 376 units outside of Oklahoma. Notably, our base of non-Oklahoma premium games increased by 208 units in the quarter as we ended the quarter with 713 premium units installed in a total of 18 markets. Additionally, with the increased geographic diversification of our products, our average revenue per day continues to rise as yields rose 3.0% year over year.

Ramsey concluded, “Awareness of our products has never been higher as we leverage the solid performance of our games in existing markets into new large market opportunities such as Nevada, Illinois and New Jersey. Our games continue to be met with strong acceptance from players and they bring a strong value proposition to our customers. We believe this combination will lead to further growth of our gaming operations and game sales businesses.”

Summary of Fiscal 2013 Third Quarter Operating Results

Multimedia Games’ fiscal 2013 third quarter revenue rose 18.9%, or $7.6 million, to $48.1 million, compared to revenue of $40.5 million in the fiscal 2012 third quarter. Fiscal 2013 third quarter revenue included approximately $34.3 million from gaming operations and approximately $13.5 million from gaming equipment and system sales, compared with $28.4 million from gaming operations and $11.7 million from gaming equipment and system sales in the year-ago period.

Gaming operations revenue in the fiscal 2013 third quarter grew 20.7% to $34.3 million driven by broad-based growth in the Company’s installed base of participation units. Multimedia Games’ domestic ending installed base increased by 2,014 units, or 19.8%, from the fiscal 2012 third quarter and by 451 units, or 3.9%, on a quarterly sequential basis. The installed base grew in substantially all the Company’s existing markets, including Oklahoma. Included in the quarter-end participation base were 713 premium participation units deployed outside of Oklahoma, an increase of 208 units, or 41.2%, on a quarterly sequential basis. Fiscal 2013 third quarter gaming operations revenue also benefited from a $0.4 million year-over-year rise in revenues related to the Company’s operation of the central determinant system for the New York Lottery.

Gaming equipment and system sales in the fiscal 2013 third quarter increased 15.3% to $13.5 million, from $11.7 million in the prior-year period. During the quarter, the Company recorded revenue of $12.4 million related to the sale of 647 new units and $0.8 million in revenue related to parts and equipment sales, compared to $10.4 million in revenue related to the sale of 543 new units and $0.7 million related to parts and equipment sales in the year-ago period. Multimedia Games sold units into 15 markets, including its first sales to casinos in New Jersey. The Company’s top three markets for unit sales in the quarter – Washington, Louisiana and Nevada – accounted for a total of 302 units sold. There was $0.2 million and $0.6 million of deferred revenues for the sale of player stations and a system in a prior-year period recognized in the fiscal 2013 and fiscal 2012 third quarter periods, respectively.

Other revenue, primarily comprised of service revenue, was approximately $0.3 million and $0.4 million in the fiscal 2013 and fiscal 2012 third quarter periods, respectively.

Total operating costs and expenses for the fiscal 2013 third quarter rose by $1.4 million, or 4.3%, to $34.1 million driven primarily by the increase in sales and placements of the Company’s gaming units and higher selling, general and administrative (“SG&A”) costs, partially offset by lower depreciation and amortization reflecting the Company’s decision to change the depreciation schedule for its gaming operations equipment, as previously reported. Total cost of goods sold increased by $1.1 million due to the increase in the number of units sold and the additions to the installed base of participation games. SG&A expenses rose 6.2%, or $0.7 million, to $12.0 million, primarily reflecting higher salary and benefit costs related to the Company’s ongoing entrance into new markets and jurisdictions. SG&A for the fiscal 2013 and fiscal 2012 third quarter periods includes non-cash stock compensation costs of approximately $1.0 million and $1.2 million, respectively. Depreciation and amortization was $8.9 million in the fiscal 2013 third quarter compared to $9.5 million in the prior-year period, primarily reflecting the previously disclosed change in the depreciable lives for gaming operations equipment from 36 months to 48 months, effective as of October 1, 2012. Research and development expenses was $4.1 million in the fiscal 2013 third quarter compared to $3.9 million in the prior-year period.

Operating income rose to $14.0 million and operating margins improved to 29.1% in the fiscal 2013 third quarter compared to 19.1% in the year-ago period, driven by the rise in revenue significantly outpacing the increase in total operating expenses as well as the continued increase in the mix of high-margin recurring revenue. For the fiscal 2013 third quarter, Multimedia Games reported net income of $8.4 million, or $0.28 per diluted share, compared to net income of $7.2 million, or $0.25 per diluted share, in the fiscal 2012 third quarter. Net income and diluted earnings per share for the fiscal 2013 third quarter reflect a tax expense rate of 38.7% while net income and diluted earnings per share in the prior-year period reflect a tax expense rate of 5.9%.

Balance Sheet Review

Multimedia Games ended the fiscal 2013 third quarter with $92.5 million in cash and net cash (total cash in excess of total debt) of $62.0 million, versus net cash of $40.5 million and $33.6 million as of September 30, 2012, and June 30, 2012, respectively. The Company generated free cash flow of $14.0 million in the quarter ended June 30, 2013, compared to $7.3 million in the year-ago period. While capital expenditures fell to $11.1 million from $12.3 million a year ago, the Company continued to invest in its installed base during the quarter.

In the third quarter of fiscal 2013, the Company repurchased approximately 56,000 shares of its common stock at an average price of $20.87 per share, excluding commissions, for total consideration of approximately $1.2 million. As of June 30, 2013, the Company had approximately $35.2 million remaining under its existing $40.0 million share repurchase authorization which was announced in November 2012. Since December 2010, the Company has repurchased approximately 2.5 million shares of its common stock.

Adam Chibib, Chief Financial Officer, commented, “The popularity of our award-winning products and their growing success in the marketplace continue to strengthen our balance sheet and drive strong free cash flow. We also continue to allocate and reinvest capital into our business to effectively enter new markets, efficiently serve existing markets and create great products that attract customer and player attention. Based on the strong financial performance of the first nine months of the fiscal year, we are raising our fiscal 2013 diluted EPS outlook to a range of $1.07 to $1.10 from our prior $0.98 to $1.02 range.”

Updated Fiscal 2013 Outlook

Multimedia Games now forecasts fiscal 2013 revenues in the range of $187.7 to $190.3 million, representing total year-over-year revenue growth of approximately 20.2% to 21.9%. The revised revenue growth forecast assumes unit sales to range from 700 to 800 units in the fiscal 2013 fourth quarter as well as a quarterly sequential increase in the installed base. Fiscal 2013 revenue guidance also includes the previously disclosed early fourth quarter reduction in revenue share percentage on approximately 1,000 units installed at the WinStar World Casino and Resort in Oklahoma which the Company expects will impact fiscal fourth quarter diluted EPS by $0.01. The current unit sales and installed base growth forecast for fiscal 2013 includes an expectation for a measured level of unit deployments in Nevada, New Jersey and Illinois in the fourth quarter as Multimedia Games continues to build its library of approved games in these jurisdictions.

The Company now expects to generate EBITDA, a non-GAAP financial measure, of $95.1 to $96.0 million in fiscal 2013, representing growth of approximately 33.8% to 35.0% over total fiscal 2012 EBITDA of $71.1 million.

Operating margins for the fiscal 2013 fourth quarter are expected to decline on a quarterly sequential basis to a range of 25% to 26% due to higher marketing costs in the quarter related to higher spending for G2E, the annual industry trade show. The Company currently expects its tax rate in the fourth quarter to be 36% to 38% and expects the full year tax rate to range from 36% to 37% compared to a benefit of 11.4% in fiscal 2012. As a result, Multimedia Games now expects to report fiscal 2013 diluted EPS of $1.07 to $1.10, representing a year-over-year increase of approximately 52.9% to 57.1% over fiscal 2012 pro-forma diluted EPS as adjusted for the new depreciation schedule and when applying a 37.0% tax rate for fiscal 2012, as set forth in the table below.

Multimedia Games cautions that market dynamics are constantly changing and as such, actual results could vary materially from the expectations noted above based on various factors, such as changes in the Company’s markets, operations, regulatory requirements, and its estimates and assumptions. See the risk factors in our publicly-filed Form 10-K’s and subsequent filings and other items as more fully described in the section below titled “Cautionary Language.”

2013 Third Quarter Conference Call and Webcast

Multimedia Games is hosting a conference call and webcast today, July 30, 2013, beginning at 9:00 a.m. ET (8:00 a.m. CT). Both the call and the webcast are open to the general public. The conference call number is 720-545-0001 (domestic or international). Please call five minutes prior to the presentation to ensure that you are connected.

Interested parties may also access the conference call live on the Internet at http://ir.multimediagames.com/events.cfm. Approximately two hours after the call has concluded, an archived version of the webcast will be available for replay at the same location.

Non-GAAP Financial Measures

See definitions of EBITDA, net cash, free cash flow, and pro-forma diluted earnings per share included in the discussion of Non-GAAP financial measures below.

About Multimedia Games Holding Company, Inc.

Through its wholly owned subsidiary, Multimedia Games Holding Company, Inc. (“Multimedia Games”) develops and distributes gaming technology. The Company is a creator and supplier of comprehensive systems, content and electronic gaming units for Native American gaming markets, as well as for commercial casinos and charity and international bingo markets. Revenue is primarily derived from gaming units installed on revenue-sharing arrangements. Multimedia Games also supplies the central determinant system for the video lottery terminals (“VLTs”) installed at racetracks in the State of New York. The company is focused on pursuing market expansion and new product development for Class II, Class III and VLT markets. Please visit www.multimediagames.com, twitter.com/MultimediaGames or facebook.com/MultimediaGames, where Multimedia Games discloses important information about the company, its sales, and its business.

Cautionary Language

This press release contains forward-looking statements based on Multimedia Games’ current expectations and projections, which are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. The words “believe”, “expect”, “continue”, “intend”, “plan”, “seek”, “estimate”, “project”, “may”, or the negative or other variations thereof or comparable terminology as they relate to Multimedia Games and its products, plans, and markets are intended to identify such forward-looking statements. All forward-looking statements are based on current expectations and projections of future events.

These forward-looking statements reflect the current views, models, and assumptions of Multimedia Games, and are subject to various risks and uncertainties that cannot be predicted or qualified and could cause actual results in Multimedia Games’ performance to differ materially from those expressed or implied by such forward looking statements. These risks and uncertainties include, but are not limited to, the ability of Multimedia Games to expand and maintain its addressable markets; maintain strategic alliances; increase unit placements, installations or its installed-base; grow its revenue, gaming operations or game sales businesses; garner new market share; secure new licenses and game approvals in new and current jurisdictions, including Nevada and New Jersey; successfully develop or place proprietary product such as premium games; comply with regulations; have its games met with approval by customers or players; or reinvest capital. Please refer to the Company’s most recent Form 10-K and subsequent filings with the Securities and Exchange Commission for a further discussion of risks and uncertainties. All forward-looking statements made herein are qualified by these cautionary statements and there can be no assurance that the actual results, events or developments referenced herein will occur or be realized. Readers are cautioned that all forward-looking statements speak only to the facts and circumstances present as of the date of this press release. Multimedia Games expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Reconciliation of GAAP to Non-GAAP measures:

This press release and accompanying schedules provide certain information regarding (i) EBITDA, (ii) net cash, (iii) free cash flow, and (iv) pro-forma diluted earnings per share, all of which may be considered non-GAAP financial measures under the rules of the Securities and Exchange Commission. The non-GAAP financial measures included in the press release are reconciled to the corresponding GAAP financial measures below, or above in this release for pro-forma diluted earnings per share, as required under the rules of the Securities and Exchange Commission regarding the use of non-GAAP financial measures. We define (i) EBITDA as net income before net interest expense, income taxes, depreciation, amortization and accretion of contract rights, (ii) net cash as cash and cash equivalents less long-term debt, (iii) free cash flow as cash flow from operating activities less the acquisition of property and equipment and leased gaming equipment, and (iv) pro-forma diluted earnings per share reflects a tax expense rate adjustment and an estimate for a change in depreciable lives of gaming operations equipment. EBITDA, net cash, free cash flow and pro-forma diluted earnings per share are not recognized financial measures under GAAP, but we believe that each is useful in measuring our operating performance. We believe that the use of the non-GAAP financial measure EBITDA enhances an overall understanding of the Company’s past financial performance, and provides useful information to the investor by comparing our performance across reporting periods on a consistent basis and the use of EBITDA by other companies in the gaming equipment sector as a measure of performance. We believe that the non-GAAP measures of net cash, free cash flow and pro-forma diluted earnings per share provide useful information to investors as each enhances the overall understanding of our operating performance.

Investors should not consider these measures in isolation or as a substitute for net income, operating income, or any other measure for determining the Company’s operating performance that is calculated in accordance with GAAP. In addition, because these measures are not calculated in accordance with GAAP, they may not necessarily be comparable to similarly titled measures employed by other companies.

Please see definition of “pro-forma diluted earnings per share” at the beginning of this release.

(GTLS) $50 Million Plus Contract to Provide LNG Equipment to PetroChina

CLEVELAND, July 30, 2013 (GLOBE NEWSWIRE) — Chart Industries, Inc. (Nasdaq:GTLS), a leading independent global manufacturer of highly engineered equipment used in the production, distribution, storage, and end-use of hydrocarbon and industrial gases, today announced that its Distribution & Storage (“D&S”) business in China has been awarded a contract to provide self-contained liquefied natural gas (“LNG”) station modules to Kunlun Energy Investment, a wholly owned subsidiary of PetroChina’s Kunlun Energy.

The contract value of this order is in excess of $50 million and is in addition to the $45 million PetroChina order the Company received and announced in April 2013. “This is the third major award from PetroChina in the last several quarters which highlights their continuing commitment to the LNG infrastructure build-out in China and we are very pleased they have chosen Chart again in recognition of our quality and product capabilities,” stated Tom Carey, President of Chart’s D&S Group. This new order is not included in the Company’s second quarter 2013 orders and backlog.

Certain statements made in this news release are or imply forward-looking statements, such as statements concerning business plans, objectives, market trends, future revenue, performance, and other information that is not historical in nature. These statements are made based on Chart’s expectations concerning future events and are subject to factors and uncertainties that could cause actual results to differ materially, such as cyclicality of product markets and vulnerability of markets to economic downturns, a delay or reduction in customer purchases, competition, fluctuations in energy prices or changes in government energy policy, management of fixed-price contract exposure, reliance on the availability of key supplies and services, pricing and availability of raw materials, modification or cancellation of customer contracts, fluctuations in foreign currency exchange rates, and economic, political, business and market risks associated with international transactions. For a discussion of these and additional factors that could cause actual results to differ from forward-looking statements, see Chart’s filings with the Securities and Exchange Commission, including Item 1A (Risk Factors) in Chart’s most recent Annual Report on Form 10-K. Chart undertakes no obligation to update or revise any forward-looking statement.

Chart is a leading independent global manufacturer of highly engineered equipment used in the production, storage and end-use of hydrocarbon and industrial gases. The majority of Chart’s products are used throughout the liquid gas supply chain for purification, liquefaction, distribution, storage and end-use applications, the largest portion of which are energy-related. Chart has domestic operations across the United States and an international presence in Asia, Australia and Europe.

For more information: http://ir.chartindustries.com/.

CONTACT: Ken Webster
         Vice President, Chief Accounting
         Officer and Controller
         216-626-1216
         ken.webster@chartindustries.com
         or
         Chris Rioux
         Manager of Investor Relations and
         Financial Planning
         216-626-1216
         chris.rioux@chartindustries.com

(LCAV) Second Quarter Financial Results Feature EPS of $0.02

CINCINNATI, July 30, 2013 /PRNewswire/ — LCA-Vision Inc. (NASDAQ: LCAV), a leading provider of laser vision correction services under the LasikPlus® brand, today announced financial and operating results for the three and six months ended June 30, 2013.

Second Quarter 2013 Financial and Operating Highlights (all comparisons are with the second quarter of 2012)

• Revenues were $22.6 million compared with $25.2 million; adjusted revenues were $22.4 million compared with $24.5 million.
• Procedure volume was 12,994 compared with 14,415.
• Medical professional and license fees decreased by $1.6 million to $4.2 million from $5.8 million. The decrease resulted from lower procedure volume coupled with lower laser fees. Laser fees were favorably impacted by the company’s purchase in April 2013 of its previously leased excimer lasers, which provided a lower per-procedure fee for all procedures performed in 2013 with this equipment, as well as for enhancement costs.
• Vision center direct costs decreased by $2.1 million to $9.4 million from $11.5 million. The decrease was a result of lower variable costs associated with the decline in procedure volume along with other savings. These savings primarily included lower laser maintenance fees from managing purchases, lower financing fees from renegotiated rates and a shift in portfolio mix, reductions in employee-related costs and lower insurance costs from favorable claims experience.
• Marketing expense decreased by $1.2 million to $5.4 million from $6.6 million, bringing marketing cost per eye to $413 from $460.
• General and administrative expenses decreased by $0.5 million to $2.9 million from $3.4 million, due primarily to reductions in employee-related costs as a result of restructuring initiatives implemented early this year.
• Depreciation expense decreased by $0.7 million to $0.5 million from $1.2 million, due to lower capital expenditures in recent years.
• Operating income was $0.3 million, a $3.6 million improvement from an operating loss of $3.3 million; adjusted operating income was $0.1 million, a $4.0 million improvement from an adjusted operating loss of $3.9 million.
• Net income was $0.5 million, or $0.02 per diluted share, a $3.7 million improvement from a net loss of $3.2 million, or $0.17 per share.

First Half 2013 Financial and Operating Highlights (all comparisons are with the first half of 2012)

• Revenues were $50.9 million compared with $61.3 million; adjusted revenues were $50.3 million compared with $59.8 million.
• Procedure volume was 29,266 compared with 35,402.
• Medical professional and license fees decreased by $3.5 million to $11.0 million from $14.5 million. The decrease resulted from lower procedure volume coupled with the impact from the company’s purchase of its previously leased excimer lasers.
• Vision center direct costs decreased by $3.9 million to $19.5 million from $23.4 million. The decrease was a result of lower variable costs associated with the procedure volume combined with other cost savings. These savings primarily included lower financing fees from renegotiated rates and a shift in portfolio mix, reductions in employee-related costs, lower insurance costs from favorable claims experience and lower laser maintenance fees from managing purchases.
• Marketing expense decreased by $1.6 million to $11.9 million from $13.5 million. Marketing cost per eye was $408 compared with $381.
• General and administrative expenses decreased by $1.0 million to $6.1 million from $7.1 million, due primarily to reductions in employee-related costs and rent from the relocation of the company’s call center as a result of restructuring initiatives implemented in early 2013.
• Depreciation expense decreased by $1.5 million to $1.0 million from $2.5 million, due to lower capital expenditures in recent years.
• Operating income was $1.3 million, a $0.9 million improvement from operating income of $0.4 million; adjusted operating income was $0.8 million, a $1.7 million improvement from an adjusted operating loss of $0.9 million.
• Net income was $1.7 million, or $0.09 per diluted share, a $1.0 million improvement from net income of $0.7 million, or $0.03 per diluted share.
• Cash and investments were $30.9 million as of June 30, 2013, compared with $34.5 million as of December 31, 2012. The cash use was due primarily to working capital changes from merchant receivables and prepaid license fee purchases in addition to restructuring payments related to severance and lease obligations for previously closed vision centers. The cash use also included start-up losses related to the company’s refractive lens and cataract business.
• In April 2013, the company purchased for $2.3 million the previously leased excimer lasers used in all of its full-service vision centers. The purchase was financed by the vendor over a three-year term at an interest rate of 3.5%.

The company provides adjusted revenues and operating income (loss) as a means of measuring performance that adjusts for the non-cash impact of accounting for separately priced extended warranties.  A reconciliation of revenues and operating income (loss) as reported in accordance with U.S. Generally Accepted Accounting Principles (GAAP) is provided at the end of this news release.  Management believes that the adjusted information better reflects operating performance and, therefore, is more meaningful to investors.

“We reported positive net income for the quarter due to a combination of cost savings from restructuring initiatives implemented early this year, new cost savings and our purchase of excimer lasers that we previously leased, which lowered the per-use fee for procedures performed with this equipment,” said LCA-Vision Chief Executive Officer Michael J. Celebrezze.  “As a result, we are reducing our estimate of the annual number of procedures to reach cash-flow breakeven for our LASIK business by 2,000 to 56,000, moving us closer to our goal of sustained profitability for this business.

“Our conversion metrics remained strong across the board and we improved average revenue per procedure to $1,722, an increase of $23 year-over-year and $5 sequentially.  We also significantly reduced our year-over-year decline in procedure volume compared with this year’s first quarter, although we anticipate that procedure volume will be negatively impacted throughout 2013 due to the lowering of the maximum contribution to flexible spending accounts mandated by the federal government at the beginning of the year.  We are taking a more integrated, synergistic approach to our advertising, managed care and partner network programs to improve marketing, while continuing to work on optimizing media mix and refining messages.  Currently, we are offering several discount promotions to support patient acquisition.

“We are pleased with the initial success of our partner network of optometrists, which is nearly self-sustaining from a financial perspective with net revenues exceeding our overhead costs.  About 1.7% of our second quarter procedure volume resulted from co-management, up from approximately 1% in the first quarter.  Among the measures underway to fully establish this program, we are focused on improving vision center staff relationships with our partners and managing patient flow.  Our plan is to add more partners throughout the current year and beyond,” added Celebrezze.

Near-Term Financial Outlook
LCA-Vision intends to manage expenses conservatively in 2013; its plans and outlook for the year include:

• The company plans to open one additional full-service licensed vision center in the second half of 2013, in addition to the two full-service licensed vision centers opened since the beginning of 2013. The company also intends to continue leveraging marketing spend by adding satellite vision centers in established LasikPlus® markets. The company has opened three satellite centers since the beginning of 2013, and plans to open at least one additional satellite center in the current year.
• The company revised its expectations for annual capital expenditures to be between $0.8 million and $1.2 million, from its prior outlook of $3.1 million to $3.5 million. The previous guidance assumed that the $2.3 million purchase of excimer lasers would be recorded at gross, impacting both capital expenditures and borrowings. As no cash changed hands in this transaction, it was reported at net.
• For the third quarter of 2013, the company expects marketing and advertising expenses to be between $4.8 million and $5.3 million.

As noted above, the company lowered its estimate for the annual number of procedures companywide necessary to reach cash-flow breakeven from its LASIK business to approximately 56,000, from the prior estimate of 58,000, after capital expenditures and debt service.  This cash-flow estimate does not include restructuring payments, or start-up losses and capital expenditures for its refractive lens and cataract business.  The company expects to continue to incur start-up losses and capital investment for its business expansion initiatives.

Conference Call and Webcast
As previously announced, a conference call and webcast will be held today beginning at 10:00 a.m. Eastern time. To access the conference call, dial 866-322-1352 (U.S. and Canada) or 706-643-6246 (international callers).  A webcast will be available in the investor relations section of LCA-Vision’s website. A replay of the call and webcast will begin approximately two hours after the live call has ended. To access the replay, dial 855-859-2056 (U.S. and Canada) or 404-537-3406 (international callers) and enter the conference ID number: 10544407.

Forward-Looking Statements 
This news release contains forward-looking statements based on current expectations, forecasts and assumptions of LCA-Vision that are subject to risks and uncertainties.  The forward-looking statements in this release are based on information available to the company as of the date hereof.  Actual results could differ materially from those stated or implied in the forward-looking statements due to risks and uncertainties associated with its business.  In addition to the risk factors discussed in the company’s Form 10-K and other filings with the Securities and Exchange Commission, there are a number of other risks and uncertainties associated with its business including, without limitation, the successful execution of cost effective marketing strategies to drive patients to its vision centers; the impact of low consumer confidence and discretionary spending; competition in the laser vision correction industry; the possibility of adverse outcomes or long-term side effects of laser vision correction and negative publicity regarding laser vision correction; the company’s ability to operate profitable vision centers and retain qualified personnel during periods of lower procedure volumes; the company’s success in expanding its services into the cataract market; additional regulatory requirements, such as for Medicare, related to cataract; the continued availability of non-recourse third-party financing for its patients on terms similar to what it has paid historically; the company’s ability to achieve profitability in its developing business expansion initiatives and the future value of revenues financed by the company and its ability to collect on such financings, which will in turn depend on a number of factors, including the consumer credit environment and the company’s ability to manage credit risk related to consumer debt, bankruptcies and other credit trends.

Further, the Food and Drug Administration’s (FDA) advisory board on ophthalmic devices currently is reviewing concerns about post-LASIK quality of life matters, and the FDA is recruiting participants for two studies on LASIK outcomes and quality of life.  The FDA or another regulatory body could take legal action against the company or others in the laser vision correction industry. The outcome of this review or legal action potentially could impact negatively the acceptance of LASIK.  In addition, the acceptance rate of new technologies and our ability to implement successfully new technologies on a national basis create additional risk.

Except to the extent required under the federal securities laws and the rules and regulations promulgated by the Securities and Exchange Commission, the company assumes no obligation to update the information included in this news release, whether as a result of new information, future events or circumstances, or otherwise.

About LCA-Vision Inc./LasikPlus®
LCA-Vision Inc., a leading provider of laser vision correction services under the LasikPlus® brand, operates 58 LasikPlus® vision centers in the United States: 51 full-service LasikPlus® fixed-site laser vision correction centers and seven pre- and post-operative LasikPlus® satellite centers. Since 1991 more than 1.3 million laser vision correction procedures have been performed at the company’s vision centers.

Earning Trust Every Moment; Transforming Lives Every Day.

For Additional Information

LCA-Vision Inc.
Effect of the Change in Accounting for Deferred Revenues on Financial Results
(Dollars in thousands)
(Unaudited)

To supplement its Consolidated Financial Statements presented in accordance with accounting principles generally accepted in the United States, LCA-Vision discusses adjusted revenues and operating income and loss. Management utilizes this information as a means of measuring performance that adjusts for the non-cash impact of the accounting for separately priced extended warranties and believes that including this additional disclosure is meaningful to investors for the same reason.

Accordingly, this news release contains non-GAAP financial measures within the meaning of Regulation G promulgated by the Securities and Exchange Commission. A reconciliation of the difference between the non-GAAP measures with the most directly comparable financial measures calculated in accordance with GAAP follows:

(SPEX) Announces its First Settlement and License Agreement

NEW YORK, July 30, 2013 /PRNewswire/ — North South Holdings Inc. (“North South”) — an intellectual property development company, today reported that its wholly owned subsidiary, CompuFill LLC, has entered into a settlement and license agreement with a leading technology company.

This is the first settlement and license agreement for the CompuFill portfolio since North South’s acquisition of CompuFill in April 2013 and commencement of its licensing campaign.  Ongoing infringement continues, and the CompuFill portfolio is currently being enforced against additional defendants.   

The CompuFill patents, each in the “on-line pharmacy automated refill system” sector, trace priority back to October 1997.

Commenting on the announcement, Anthony Hayes, North South CEO, stated, “The value of having this suite of patents cannot be emphasized enough. Our team of patent monetization experts brought this opportunity to North South only a few short months ago and we have already started generating revenue. This is a great example of how North South is working to drive value for our investors.”

About North South Holdings Inc.
North South Holdings Inc. was formed on November 9, 2012 to seek business opportunities in which to acquire patents from various entities and monetize those patents through sales, litigation or licensing.  North South recently entered into an agreement to be acquired by Spherix Incorporated (NASDAQ: SPEX).

About Spherix Incorporated
Spherix Incorporated (NASDAQ: SPEX) was launched in 1967 as a scientific research company. Spherix presently offers a diversified commercialization platform for protected technologies. The company continues to work on life sciences and drug development and presently is exploring opportunities in nutritional supplement products relying on its D-Tagatose natural sweetener as a GRAS ingredient. Spherix is committed to advancing innovation by active participation in all areas of the patent market. Spherix draws on portfolios of pioneering technology patents to partner with and support product innovation. Through its recently announced acquisition of several hundred patents issued to Harris Corporation Spherix intends to expand its activities in wireless communications and telecommunication sectors including antenna technology, Wi-Fi, base station functionality, and cellular.

Forward Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While North South believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties. Thus, actual results could be materially different. North South expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact Information:
Anthony Hayes, CEO
North South Holdings Inc.
110 Greene Street; Suite 403
New York, NY 10012
347-855-6146
anthony@northsouthholdings.com
www.northsouthholdings.com

(GALE) to Present at the 8th Annual JMP Securities Healthcare Conference

LAKE OSWEGO, Ore., July 2, 2013 (GLOBE NEWSWIRE) — Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that Mark J. Ahn, Ph.D., President & CEO, will present a corporate update at the 8^th Annual JMP Securities Healthcare Conference. The presentation will take place on Wednesday, July 10, 2013 at 10:30 a.m. ET at The St. Regis Hotel in New York, NY.

The presentation will be webcast and available on the Investors section of the Company’s website at www.galenabiopharma.com.

About Galena Biopharma

Galena Biopharma, Inc. (Nasdaq:GALE) is a Portland, Oregon-based biopharmaceutical company developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. For more information please visit us at www.galenabiopharma.com.

CONTACT: Remy Bernarda
         Senior Director, Communications
         (503) 405-8258
         rbernarda@galenabiopharma.com

(DOVR) Announces Earnings Release Date and Q2 Webcast

Janet Nittmann

Tel 978-952-8062 x218

Email Contact

(MWIV) Announces 2013 Third Quarter Results and Business Outlook Updates

Contact:
Mary Pat Thompson
Senior Vice President of Finance and Administration and Chief Financial Officer
(208) 955-8930

(NSPR) Announces First Patient Enrolled in U.S. Registration Trial for MGuard™ Prime EPS

BOSTON and TEL AVIV, Israel, July 29, 2013 /PRNewswire/ — InspireMD, Inc. (NYSE MKT: NSPR) (“Inspire” or the “Company”), a leader in embolic protection stents, said the first patient has been enrolled in the Master II IDE clinical trial to evaluate the safety and effectiveness of the MGuard™ Prime Embolic Protection Stent (EPS) in patients suffering from ST Elevation Myocardial Infarction (STEMI).

The multi-center, randomized trial is expected to include up to 70 sites in the U.S. and Europe and as many as 1,114 patients. The results are intended to support the Company’s Investigational Device Exemption (IDE) application with the U.S. Food and Drug Administration (FDA) to market the MGuard™ Prime MicroNet™ covered coronary stent system in the U.S.

The trial has two co-primary endpoints: superiority in complete ST resolution and non-inferiority in death and target vessel myocardial infarction. In addition, a 356 patient sub-study will be conducted to assess the effect of the MGuard Prime™ EPS on infarct size, as measured by Magnetic Resonance Imaging (MRI).

The trial’s principal investigators are Gregg Stone, M.D. of New York Presbyterian Hospital and Columbia University Medical Center in New York City, and Jose P. S. Henriques, M.D. of the Academic Medical Center in Amsterdam.

The first procedure was performed at ZNA Middelheim by Stefan Verheye, M.D. “Distal embolization and no-reflow are severe concerns when treating our STEMI patients. From our experience over the last two years, the MGuard Prime EPS has improved patient outcome and led to brilliant results, thanks to its unique protective mesh,” said Dr. Verheye. “I am excited about participating in the MASTER II Trial and enthusiastic about its potential impact on patient care worldwide.”

“Enrolling our first patient in MASTER II is a very important milestone for the company. We are committed to advancing patient care through robust clinical research,” said Alan Milinazzo, InspireMD’s CEO and President. “MASTER II provides another important opportunity for us to demonstrate the safety of MGuard EPS and to validate its effectiveness compared to current standard of care treatment for STEMI patients.”

The FDA trial, known as MASTER II (MGuard™ for Acute ST Elevation Reperfusion), is the second in a series of randomized clinical studies intended to validate the safety and effectiveness of the MGuard™ EPS platform and achieve registration with appropriate regulatory authorities worldwide.

InspireMD’s MGuard™ EPS technology previously yielded positive results in the MASTER Trial findings, showing a statistically and clinically significant acute advantage with regard to ST segment resolution. As a result, the MGuard™ EPS may hold the potential to lower the incidence of adverse events and improve the survival of patients suffering from acute myocardial infarction.

About Stenting and MGuard™ EPS

Standard stents were not engineered for heart attack patients. They were designed for treating stable angina patients whose occlusion is different from that of an occlusion in a heart attack patient.

In acute heart attack patients, the plaque or thrombus is unstable and often breaks up as the stent is implanted causing downstream blockages (some of which can be fatal) in a significant portion of heart attack patients.

The MGuard™ EPS is integrated with a precisely engineered micro net mesh that prevents the unstable arterial plaque and thrombus (clots) that caused the heart attack blockage from breaking off.

While offering superior performance relative to standard stents in STEMI patients with regard to ST segment resolution, the MGuard™ EPS requires no change in current physician practice – an important factor in promoting acceptance and general use in time-critical emergency settings.

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MGuard technology to make its products the industry standard for embolic protection stents and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.

InspireMD intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures. InspireMD’s common stock is quoted on the NYSE MKT under the ticker symbol NSPR.

MGuard™ EPS is CE Mark approved. It is not approved for sale in the U.S. by the FDA at this time.

Forward-looking Statements:

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multi-national companies, (v) product liability claims, (vi) our limited manufacturing capabilities and reliance on subcontractors for assistance, (vii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (viii) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (ix) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (x) our reliance on single suppliers for certain product components, (xi) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Transition Report on Form 10-K/T and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

For additional information:
InspireMD Desk
Redington, Inc.
+1-212-926-1733
+1-203-222-7399
inspiremd@redingtoninc.com

(PRAN) Doses First Patient in PBT2 Alzheimer’s Extension Study

(URRE) Announces Second Quarter Conference Call and Webcast

LEWISVILLE, Texas, July 29, 2013 (GLOBE NEWSWIRE) — Uranium Resources, Inc. (Nasdaq:URRE) (“URI”) will host a conference call and webcast on Friday, August 9, 2013 at 11:30 a.m. ET. During the call, Christopher M. Jones, President and CEO, and Jeffrey L. Vigil, Vice President and Chief Financial Officer, will provide an update on URI’s strategies, outlook, and progress in advancing its Texas and New Mexico properties. A question-and-answer session will follow.

The URI conference call can be accessed by calling (201) 689-8471. The live webcast can be monitored at www.uraniumresources.com.

A telephonic replay will be available from 2:30 p.m. ET the day of the teleconference until Friday, August 16, 2013. To listen to the archived call, dial (858) 384-5517 and enter replay pin number 417986. Alternatively, the webcast replay can be heard on the Company’s website and a transcript will also be posted, once available.

About Uranium Resources, Inc.

Uranium Resources, Inc. explores for, develops and mines uranium. Since its incorporation in 1977, URI has produced uranium by in-situ recovery (ISR) methods in the state of Texas and currently has a number of initiatives underway to return the Company to production. URI has over 206,600 acres of uranium mineral holdings and 144.8 million pounds of in-place mineralized uranium material in New Mexico and an NRC license to produce up to 3 million pounds of uranium per year. URI has an additional 664,000 pounds of in-place reserves in Texas. The Company acquired these properties over the past 20 years along with an extensive information database of historic drill hole logs, assay certificates, maps and technical reports.

Uranium Resources routinely posts news and other information about the Company on its website at www.uraniumresources.com.

CONTACT: Investor Contact:
         Deborah K. Pawlowski
         Kei Advisors LLC
         Phone: 716.843.3908
         Email: dpawlowski@keiadvisors.com

(SPEX) Closes Rockstar Patent Acquisition Transaction

Spherix Closes Rockstar Patent Acquisition Transaction and Enhances Its Patent Portfolio in Wireless Communications and Telecommunication Sectors — Rockstar Acquires Equity Stake in Spherix-Venture to Be Headed by Seasoned Monetization Executive

(BKR) Enters into Agreement to Be Acquired by Integrated Mission Solutions

Michael Baker Corporation (“Baker”) (NYSE MKT:BKR) announced today that it has entered into a definitive merger agreement to be acquired by Integrated Mission Solutions, LLC (“IMS”), an affiliate of DC Capital Partners, LLC (“DC Capital”).

Under the terms of the agreement, which has been unanimously approved by Baker’s Board of Directors, Baker shareholders will receive $40.50 in cash for each share of common stock that they own, in a transaction valued at $396.9 million. The per share price represents a 37% premium to Baker’s closing share price of $29.60 on July 26, 2013, a 55% premium to the average 90-day share price, and a 93% premium to the share price on December 18, 2012, the day before DC Capital publicly proposed to acquire Baker.

Under the terms of the agreement, a subsidiary of IMS will commence a tender offer to acquire all of the outstanding Baker common shares. Baker’s Board of Directors unanimously approved the offer. Any shares not tendered in the offer will be acquired in a merger at the same cash price as paid in the tender offer. Closing of the tender offer is conditioned upon customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The transaction is expected to close late in the third quarter or early in the fourth quarter of 2013.

“Baker is a well-known and highly regarded firm in the architecture, engineering and construction services industry. The transaction, which we believe delivers outstanding value to shareholders, results from a thorough, extensive strategic assessment process initiated by the Board early this year,” said Baker’s Robert N. Bontempo, Chairman of the Board of Directors. “We believe that this union with IMS will provide substantial value to shareholders, while reinforcing our commitment to our customers to continuously provide them with excellent service and high quality professional services.”

In an effort to preserve Baker’s heritage and culture, IMS has agreed to retain the Baker name, maintain Baker’s presence in the Pittsburgh area, and keep the current organization and staff of Baker essentially intact.

Thomas J. Campbell, Chairman of IMS and Founder of DC Capital, said, “This is a significant step for both companies. The combination of Michael Baker and IMS will create a company with over $1.0 billion in revenue, approximately 5,000 employees, and a platform with global reach. IMS has a strong presence internationally with a history of operating on all five continents. This geographic footprint in support of our customers in growth areas such as infrastructure, development, intelligence, and technology combined with Michael Baker’s complementary capabilities, highly certified, security cleared workforce, and distinctive North American presence will greatly enhance our collective ability to manage and execute larger projects.”

Mr. Campbell also stated, “Michael Baker and IMS share a common employee and community-oriented culture. We both believe that our people are our most important asset and we share a commitment to investing in their professional development. Similarly, we believe our collective mission is to help our customers achieve their goals and objectives. Michael Baker has a depth of talent in all ranks within the organization. Michael Baker has a talented management team and we have been impressed by the interim leadership provided by H. James McKnight, Chief Legal Counsel, and Michael J. Zugay, Chief Financial Officer, who together form the Office of the Chief Executive. Our goal is to ensure a continuity of Michael Baker’s over 70 year legacy and culture. As such, the Michael Baker name and brand will remain, three members of the Michael Baker Board of Directors will join the combined company Board, and the headquarters for Michael Baker will remain in Moon Township, Pennsylvania. As a Pennsylvania company we have been impressed by Michael Baker’s commitment to supporting the Pennsylvania community and we support the protection of this tradition.”

The transaction will be financed through a combination of cash provided by IMS as well as debt financing that has been committed, subject to the terms of a commitment letter, by Jefferies Finance LLC. Jefferies LLC is also serving as exclusive financial advisor to IMS and DC Capital. Arnold & Porter LLP is serving as legal advisor to IMS and DC Capital.

Houlihan Lokey is serving as financial advisors to Baker in this transaction. Jones Day and K&L Gates are serving as legal advisors to Baker.

About Baker

Michael Baker Corporation (www.mbakercorp.com) provides engineering, design, planning and construction services for its clients’ most complex challenges worldwide. The firm’s primary business areas are architecture, aviation, defense, environmental, geospatial, homeland security, municipal & civil, oil & gas, rail & transit, telecommunications & utilities, transportation, urban development and water. With more than 3,000 employees in over 100 offices across the United States, Baker is focused on creating value by delivering innovative and sustainable solutions for infrastructure and the environment. Learn more at www.mbakercorp.com.

About Integrated Mission Solutions, LLC

Integrated Mission Solutions, LLC (“IMS”) is a rapidly growing, global provider of a comprehensive continuum of mission critical services and solutions including, but not limited to: Engineering and Construction, Technical and Professional Services, Full Life Cycle Support, Strategic Consulting and Competitive Intelligence, Intelligence Operational Support and Training, Intelligence Community Information Technology Solutions, Research, Test, Evaluation, Procurement, and Software Development, and Enterprise and Communications Solutions. IMS has a diverse customer base with a primary focus on the United States Intelligence Community, Department of State, Department of Defense, Department of Homeland Security, United States Army Corps of Engineers, and other federal agencies. Learn more at www.integratedmissionsolutionsllc.com.

About DC Capital Partners, LLC

DC Capital Partners, LLC is a private investment firm headquartered in Washington, DC focused on making control investments in middle market companies that provide differentiated and innovative services and solutions to the United States government. DC Capital’s investment strategy emphasizes sectors that it believes offer the most compelling growth opportunities including, but not limited to, Intelligence, Information Technology, Development, Security, Infrastructure, Construction, and Environmental services. Learn more at www.dccapitalpartners.com.

Important Information About the Tender Offer

This news release is not an offer to purchase or a solicitation of an offer to sell securities of Baker. The planned tender offer by Integrated Mission Solutions for all of the outstanding shares of common stock of Baker has not been commenced. On commencement of the tender offer, Integrated Mission Solutions will mail to Baker’s shareholders an offer to purchase and related materials and Baker will mail to its shareholders a recommendation statement with respect to the tender offer. Integrated Mission Solutions will file its offer to purchase with the Securities and Exchange Commission (“SEC”) on Schedule TO, and Baker will file its recommendation statement with the SEC on Schedule 14D-9. Baker shareholders are urged to read these materials carefully when they become available, since they will contain important information, including the terms and conditions of the offer. Baker shareholders may obtain a free copy of these materials (when they become available) and other documents filed by Integrated Mission Solutions or Baker with the SEC at the website maintained by the SEC at www.sec.gov. These materials also may be obtained (when they become available) for free by contacting the information agent in the tender offer (when one is selected).

Note with respect to Forward-Looking Statements:

(This press release contains forward-looking statements with respect to the tender offer and related transactions, including the benefits expected from the acquisition and the expected timing of the completion of the transaction. When used in this press release, the words “can,” “will,” “intends,” “expects,” “is expected,” similar expressions and any other statements that are not historical facts are intended to identify those assertions as forward-looking statements. Such statements are based on a number of assumptions that could ultimately prove inaccurate, and are subject to a number of risk factors, including uncertainties regarding the timing of the closing of the transaction and the risk that the transaction will not close. Factors that could cause actual results to differ materially include the following: the risk that a majority of Baker shares do not tender their stock in the tender offer, the risk that the company experiences a material adverse change giving IMS the right not to close the transaction, the risk that IMS is unable to close on its financing and the risk that Baker’s businesses will suffer due to uncertainty related to the transaction, the competitive environment in our industry and competitive responses to the transaction. Baker does not assume any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Further information on factors that could affect Baker’s financial results is provided in documents filed by Baker with the SEC, including Baker’s recent filings on Form 10-Q and Form 10-K.)

(SNTA) Announces ENCHANT-1 Breast Cancer Results

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that preliminary results from the ENCHANT-1 clinical trial, which evaluates ganetespib monotherapy in patients with newly diagnosed locally advanced or metastatic HER2 positive or triple-negative breast cancer (TNBC), achieved the prespecified criteria for advancing to the second stage of the trial.

Of the initial five HER2-positive patients enrolled in the study, two achieved objective tumor response and two achieved stable disease (SD) within the three cycles of treatment on study (12 weeks). Of the initial ten TNBC patients enrolled and evaluable for response, two achieved objective tumor response and three achieved SD following treatment with ganetespib monotherapy.

ENCHANT-1 is a ‘window-of-opportunity’ study designed to evaluate the clinical activity of single-agent ganetespib over a 12-week period preceding standard first line treatment. The protocol specifies advancing to the second stage of enrollment in each cohort if there was at least one objective tumor response out of the initial fifteen evaluable patients specified for Stage 1. This criterion was achieved in both cohorts, and therefore both cohorts will continue to enroll patients up to a total of 33 evaluable patients per cohort.

Metabolic response was also assessed in the study, by comparing baseline and week 3 PET scans. Of the five HER2-positive patients, four achieved metabolic responses. Of the 13 TNBC patients with post-baseline PET scans, six achieved metabolic response.

“Ganetespib appears to be what many of us in the Hsp90 field have been seeking for many years: a well tolerated, highly potent Hsp90 inhibitor that is clinically active in tough-to-treat cancers,” said Dr. Neil Spector, Co-Director of Developmental Therapeutics Program, Duke University and an investigator on the trial. “Given the known role of Hsp90 in fueling breast cancer growth and metastasis, and the single-agent activity seen with ganetespib, I believe this compound has potential to be an important new therapy for women with breast cancer.”

Among the patients enrolled in the study is a 68 year old woman diagnosed with inoperable TNBC, including extensive disease that had spread to her lymph nodes. The week 3 PET scan showed metabolic response in all lesions and the week 12 physical exam showed no evidence of tumor. Treatment was adjudicated a complete clinical response, and her disease was restaged from inoperable to operable. Earlier this month, she successfully completed a mastectomy with curative intent.

“It is quite remarkable to see such a strong clinical response in this devastating disease, particularly with a single-agent regimen this well tolerated,” said Dr. Tamas Hickish, Professor at the Royal Bournemouth Hospital, Dorset, UK, the treating physician and an investigator on the study. “This outcome strongly supports the further investigation of ganetespib either as a single-agent or in combination with standard of care treatments used in this setting.”

Consistent with prior experience in over 700 patients treated with ganetespib to date, the most common adverse event seen with ganetespib in the ENCHANT-1 trial was mild to moderate, transient diarrhea, which was generally manageable with standard medication.

“These encouraging findings confirm prior signals of clinical activity seen with ganetespib in breast cancer,” said Dr. Iman El-Hariry, Vice President of Clinical Research at Synta. “The favorable safety profile, clear single-agent clinical activity, and strong rationale for combination therapy suggest ganetespib may have broad potential utility in breast cancer. Taxanes in particular are widely used in breast cancer. The positive results for the combination of ganetespib with docetaxel in lung cancer provide strong rationale for exploring the taxane combination regimen in breast cancer as well.”

The expansion of the ENCHANT-1 trial will also allow for evaluation of the combination of weekly paclitaxel and ganetespib. Separately, an investigator-sponsored study evaluating the combination of ganetespib, paclitaxel, and trastuzumab in HER2-positive patients is initiating at MSKCC and NYU.

Results from ENCHANT-1 are expected to be presented at a medical meeting later this year.

About Ganetespib

Ganetespib, an investigational drug candidate, is a selective inhibitor of heat shock protein 90 (Hsp90), a molecular chaperone which controls the folding and activation of a number of client proteins that drive tumor development and progression. Many solid and hematologic tumors are dependent on Hsp90 client proteins including proteins involved in “oncogene addiction” (ALK, HER2, mutant BRAF and EGFR, androgen receptor, estrogen receptor, JAK2); proteins involved in resistance to chemotherapy and radiation therapy (ATR, BCL2, BRCA1/2, CDK1/4, CHK1, survivin, and WEE1); proteins involved in angiogenesis (HIF-1alpha, VEGFR, PDFGR, and VEGF); and proteins involved in metastasis (MET, RAF, AKT, MMPs, HIF-1alpha, and IGF-1R). In preclinical models, inhibition of Hsp90 by ganetespib results in the inactivation, destabilization, and eventual degradation of these cancer-promoting proteins. Ganetespib is being evaluated in over 20 clinical trials including a Phase 3 trial in non-small cell lung adenocarcinoma, as well as additional trials in lung, breast, colorectal, and hematologic malignancies. Information on these trials can be found at www.clinicaltrials.gov.

About the ENCHANT-1 Clinical Trial

ENCHANT-1 is a proof-of-concept, ”window-of-opportunity” trial designed to evaluate single-agent ganetespib safety and clinical activity in locally advanced or first line metastatic HER2-positive and triple-negative breast cancer. The trial will also evaluate the combination of ganetespib with paclitaxel. More information about this trial can be found at www.clinicaltrials.gov (NCT01677455)

About Breast Cancer

Breast cancer is the most frequent cancer in women, accounting for 458,000 deaths worldwide in 2008, according to the World Health Organization. In the U.S., the American Cancer Society estimates that about 297,000 cases of breast cancer will be diagnosed in 2013. Breast cancer is often characterized in the context of three biomarkers: ER/PR positive, HER2-positive, or negative for all three (triple-negative). Standard treatment for the first two categories includes therapies targeting hormonal or HER2 signaling pathways. There are no established targeted therapies for patients with triple-negative disease, which accounts for approximately 15% of all breast cancer and is associated with poor patient prognosis.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and discovery capabilities. For more information, please visit www.syntapharma.com.

Safe Harbor Statement

This media release may contain forward-looking statements about Synta Pharmaceuticals Corp. Such forward-looking statements can be identified by the use of forward-looking terminology such as “will”, “would”, “should”, “expects”, “anticipates”, “intends”, “plans”, “believes”, “may”, “estimates”, “predicts”, “projects”, or similar expressions intended to identify forward-looking statements. Such statements, including statements relating to the developments and progress of our clinical and preclinical programs, reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including those described in “Risk Factors” of our Form 10-K for the year ended December 31, 2012 as filed with the Securities and Exchange Commission. Synta undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

(MNTA) Announces Potential for 2014 Market Entry of Generic Copaxone®

Federal Circuit Invalidates 2015 Copaxone Patent

CAMBRIDGE, Mass., July 26, 2013 (GLOBE NEWSWIRE) — Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today announced that the United States Court of Appeals for the Federal Circuit (the “Federal Circuit”) invalidated several Copaxone patents asserted against the company by Teva Pharmaceuticals, including the only asserted patent to expire in September 2015. Today’s decision narrows a 2012 decision by the District Court for the Southern District of New York (the “District Court”) and potentially clears the way for market entry of generic Copaxone as early as May 2014, the expiration date of the remaining asserted patents, pending U.S. Food and Drug approval (FDA).

“We are extremely pleased with today’s ruling,” said Craig Wheeler, President and Chief Executive Officer of Momenta. “Given the decision, we and Sandoz will continue to work with FDA to advance review of the ANDA for generic Copaxone in order for this product to be approved and available to patients as soon as possible.”

The case involved nine patents asserted by Teva for patent infringement associated with submission of an Abbreviated New Drug Application (ANDA) to FDA for generic Copaxone. The asserted patents included seven FDA Orange Book patents and one non-Orange Book patent expiring in May 2014 and one non-Orange Book patent expiring in September 2015. The case is Teva Pharmaceuticals v. Sandoz and Momenta and Mylan et al., case numbers 2012-1567, -1568, -1569, -1570.

In 2012, the District Court found all nine patents valid and infringed and issued injunctions enjoining FDA from approving any ANDA for generic Copaxone until May 2014, and enjoining parties in the case from making, using, offering for sale, or selling generic Copaxone until September 2015. Today’s decision means that the injunctions will be modified to reflect the Federal Circuit’s decision, potentially permitting generic Copaxone to be available to patients when remaining asserted patents covering Copaxone expire in 2014.

The ANDA for generic Copaxone is under FDA review and continues to advance. Momenta and Sandoz remain confident that the ANDA will be approved under the 505(j) pathway as an interchangeable generic Copaxone.

About M356, a generic version of Copaxone (glatiramer acetate injection)

M356 (glatiramer acetate injection) is a generic version of Copaxone, a synthetic polypeptide medicine, developed in collaboration with Sandoz and currently under review by FDA. Copaxone is prescribed for patients with relapsing-remitting multiple sclerosis, a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. Copaxone is one of the leading products marketed for treating multiple sclerosis.

About the Orange Book

The “Orange Book” is officially recognized as the FDA’s list of Approved Drug Products with Therapeutic Equivalence Evaluations.

About Momenta

Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex mixture drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilars and potentially interchangeable biologics, and to the discovery and development of novel medicines.

To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.

Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

Special Note Regarding Forward-Looking Statements

Statements in this press release regarding management’s future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to its beliefs and intentions related to the outcome of litigation with Teva Pharmaceuticals and our ability to achieve approval of generic Copaxone (M356) product, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as “anticipate,” “believe,” “could,” “could increase the likelihood,” “hope,” “target,” “project,” “goals,” “potential,” “predict,” “might,” “estimate,” “expect,” “intend,” “is planned,” “may,” “should,” “will,” “will enable,” “would be expected,” “look forward,” “may provide,” “would” or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors referred to in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 filed with the Securities and Exchange Commission under the section “Risk Factors,” as well as other documents that may be filed by Momenta from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company’s actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Momenta is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Lora Pike
         Senior Director, Investor Relations and
         Corporate Communications
         lpike@momentapharma.com
         617-395-5189

(AEHR) Announces $2.5 Million in Orders From Leading IC Manufacturer

FREMONT, Calif., July 26, 2013 (GLOBE NEWSWIRE) — Aehr Test Systems (Nasdaq:AEHR), a worldwide supplier of semiconductor test and burn-in equipment, today announced it has received over $2.5 million in production orders for its burn-in and test systems from a leading manufacturer of advanced logic integrated circuits (ICs) for automotive, embedded processing, digital signal processing and analog applications. The orders include down payments to lock in delivery slots and volume pricing discounts.

The orders are for multiple Advanced Burn-in and Test Systems (ABTS™) and a follow-on MAX^TM system. The ABTS systems feature a new low-cost high-volume configuration targeted at production test and burn-in of lower-power devices. This new ABTS offers the option of high voltage Device Power Supplies configurable with 60V, 80V, 150V or 230V programmable voltage ranges, which are needed for automotive and power-line applications. Shipments of this new ABTS configuration are expected to begin in the fourth quarter of calendar year 2013.

“We are pleased to receive these orders for production test and burn-in systems,” said Carl Buck, vice president of marketing at Aehr Test Systems. “The new ABTS system configuration offers over 50% more device test capacity than our previous MAX family of production test and burn-in systems. Importantly, this new ABTS is designed to allow the customer to continue to use their extensive inventory of MAX-style burn-in boards on the ABTS while also offering the increased capacity for new devices. This ABTS configuration extends the capabilities of our MAX systems by providing an increase to 128 I/O channels and 8 unique device power supplies per burn-in board, in addition to the new high-voltage supplies.

“The new configuration extends our already successful ABTS-Pi system, which features Individual Temperature Control of each device for high power applications, to provide a lower cost and higher parallel solution for automotive, standard logic and high voltage applications,” Buck concluded.

The ABTS family of products is based on a new hardware and software platform that is designed to address not only today’s devices, but also future devices for many years to come. It can test and burn-in both logic and memory devices, including resources for high pin-count devices and configurations for high-power and low-power applications. The ABTS system can be configured with up to 72 burn-in boards with up to 320 I/O channels each and 32M of test vector memory per channel. The ABTS system is optimized for use with the Sensata iSocket* Thermal Management Technology, which provides a scalable cost-effective solution using individual device temperature control for ICs up to 75 watts or more. Individual temperature control enables high-power devices with a broad range of power dissipation to be burned-in simultaneously in a single burn-in chamber while maintaining a precise device temperature. The ABTS system also uses N+1 redundancy technology for many key components in the system to maximize system uptime.

*iSocket is a trademark of Sensata Technologies, Inc.

About Aehr Test Systems

Headquartered in Fremont, California, Aehr Test Systems is a worldwide provider of test systems for burning-in and testing logic and memory integrated circuits and has an installed base of more than 2,500 systems worldwide. Increased quality and reliability needs of the Automotive and Mobility integrated circuit markets are driving additional test requirements, capacity needs and opportunities for Aehr Test products in package and wafer level test. Aehr Test has developed and introduced several innovative products, including the ABTS and FOX^TM families of test and burn-in systems and the DiePak® carrier. The ABTS system is used in production and qualification testing of packaged parts for both low-power and high-power logic as well as all common types of memory devices. The FOX system is a full wafer contact test and burn-in system used for burn-in and functional test of complex devices, such as leading-edge memories, digital signal processors, microprocessors, microcontrollers and systems-on-a-chip. The DiePak carrier is a reusable, temporary package that enables IC manufacturers to perform cost-effective final test and burn-in of bare die. For more information, please visit the Company’s website at www.aehr.com.

Safe Harbor Statement

This press release contains certain forward-looking statements based on current expectations, forecasts and assumptions that involve risks and uncertainties. These statements are based on information available to Aehr Test as of the date hereof and actual results could differ materially

from those stated or implied due to risks and uncertainties. Forward-looking statements include statements regarding expected initial shipping dates of our ABTS systems. The risks and uncertainties that could cause our results to differ materially from those expressed or implied by such forward-looking statements include, without limitation, general world economic conditions and events, the state of the semiconductor equipment market, our ability to maintain sufficient cash to support operations, acceptance by customers of the ABTS technology, acceptance by customers of the ABTS systems shipped upon receipt of a purchase order and the ability of new products to meet customer needs or perform as described. See Aehr Test’s recent 10-K, 10-Q and other reports from time to time filed with the Securities and Exchange Commission for a more detailed description of the risks facing our business. The Company disclaims any obligation to update information contained in any forward-looking statement to reflect events or circumstances occurring after the date of this press release.

CONTACT: Aehr Test Systems
         Carl Buck
         V.P. of Marketing
         (510) 623-9400 x381

         Financial Relations Board
         Marilynn Meek
         Analyst/Investor Contact
         (212) 827-3773

(ETRM) to Host Second Quarter 2013 Financial Results Conference Call

EnteroMedics to Host Second Quarter 2013 Financial Results Conference Call and Provide Business Update

(WAVX) to Complete $1.5 Million Stock Offering

Company:
Gerard T. Feeney
CFO
info@wavesys.com
413-243-1600

Investor Relations:
David Collins, Eric Lentini
wavx@catalyst-ir.com
212-924-9800

(GENT) Receives Positive Opinion From EMA’s CHMP for Defitelio

VILLA GUARDIA, Italy, July 26, 2013 (GLOBE NEWSWIRE) — Gentium S.p.A. (Nasdaq:GENT) (the “Company”) announced today that, following its request for re-examination, the European Medicines Agency’s (“EMA”) Committee for Medicinal Products for Human Use (“CHMP”) adopted a positive opinion for Defitelio recommending a Marketing Authorization Application (“MAA”) under exceptional circumstances, for the treatment of severe hepatic veno-occlusive disease (“VOD”) in adults and children undergoing hematopoietic stem cell transplantation therapy.

The European Commission (“EC”) will review the positive opinion from the CHMP, as they have the authority to grant marketing authorization. The EC generally follows the recommendations of the CHMP and delivers its final decision within three months, which will be applicable to all European Union (EU) countries. Upon approval, each member state will then determine the individual country price and the level of reimbursement.

Dr. Khalid Islam, Chairman and Chief Executive Officer of Gentium S.p.A., welcomed the decision saying “We are delighted for this positive recommendation for Defitelio. This outcome from the CHMP meeting is an important milestone for the Company and represents the culmination of a great deal of work by many people. If approved, Defitelio would become the first drug for VOD in the current treatment setting. We look forward to the ratification of the CHMP recommendation by the European Commission.”

Dr. Paul Richardson, RJ Corman Professor Of Medicine, Harvard Medical School, Clinical Director of the Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA (USA) and principal investigator stated, “We believe that Defitelio will represent a very important therapeutic option for patients undergoing hematopoietic stem-cell transplantation. It provides a potentially life-saving treatment for severe VOD, a complication with both a very high mortality rate and for which there are no other approved therapies.”

Dr. Alejandro Madrigal, President of the European Group for Blood and Morrow Transplantation (“EBMT”), the largest professional body in field of Hematopoietic Stem Cell transplantation, said “The EBMT guidelines, prepared by over 30 leading experts, recommend Defitelio as a therapy proven to be of value in the treatment of severe VOD. The EBMT considers that the published evidence of efficacy and safety, and also the extensive clinical experience, support the value of Defitelio in the treatment of VOD.”

About Approval under Exceptional Circumstances

When the applicant can show that it is not possible to provide comprehensive data on efficacy and safety of a medicine due to the rarity of the condition it is intended for, or limited knowledge in the therapeutic area or ethical considerations involved in the collection of such data, the CHMP may recommend that a medicine is approved under “exceptional circumstances”. Also in such cases, the applicant is given obligations to fulfil, particularly relating to the safety. These are re-assessed every year until the approval can be converted into a normal one.

About VOD

Veno-occlusive disease (VOD) is a potentially life-threatening condition, which typically occurs as a significant complication of stem cell transplantation. Certain high-dose conditioning regimens used as part of stem cell transplantation can damage the lining cells of hepatic blood vessels and result in VOD, a blockage of the small veins in the liver that leads to liver failure and can result in significant dysfunction in other organs such as the kidneys and lungs (so-called severe VOD). Stem cell transplantation is a frequently used treatment modality following high-dose chemotherapy and radiation therapy for hematologic cancers and other conditions in both adults and children. At present there is no approved agent for the treatment or prevention of VOD in the United States or the European Union.

About Gentium

Gentium S.p.A., located in Como, Italy, is a biopharmaceutical company focused on the development and manufacture of drugs to treat and prevent a variety of diseases and conditions, including vascular diseases related to cancer and cancer treatments. Defibrotide, the Company’s lead product candidate, is an investigational drug that has been granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) and Orphan Medicinal Product Designation by the European Medicines Agency, both to treat and to prevent VOD, as well as Fast Track Designation by the U.S. FDA to treat VOD.

Cautionary Note Regarding Forward-Looking Statements

This release contains “forward-looking statements” that involve a number of risks and uncertainties the outcome of which could materially and/or adversely affect actual future results and the market price of Gentium’s securities. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” the negative of these terms and other comparable terminology. These statements are not historical facts but instead represent the Company’s belief regarding future results, many of which, by their nature, are inherently uncertain and outside the Company’s control. It is possible that actual results, including with respect to the possibility of any future regulatory approval, may differ materially from those anticipated in these forward-looking statements. For a discussion of some of the risks and important factors that could affect future results, see the discussion in our Form 20-F filed with the Securities and Exchange Commission under the caption “Risk Factors.”

CONTACT: Gentium S.p.A.
         Salvatore Calabrese, +39 031-5373-260
         SVP & CFO
         scalabrese@gentium.it

         or

         The Trout Group
         Chelsea Wheeler +1 646 378 2941
         cwheeler@troutgroup.com

(BLIN) iAPPS ds Platform Selected by Leading National ISO Network

BURLINGTON, Mass., July 25, 2013 (GLOBE NEWSWIRE) — Bridgeline Digital, Inc. (Nasdaq:BLIN), The Digital Engagement Company™, today announced that a leading national provider of outsourced, face-to-face sales teams has selected the iAPPS ds platform to power over 300 next generation, mobile-friendly websites for each of their locations throughout the United States. The customer caters to a diverse client base of companies in a wide range of industries that includes telecommunications, office products, retail, energy, and financial services. With this deployment, Bridgeline now powers nearly 5,000 customer websites on the iAPPS ds platform, the premiere solution for franchise and large dealer networks.

iAPPS ds has a proven track record providing franchises and large dealer networks a unified platform that empowers local franchisees to personalize content, improve web visibility with Search Engine Optimization (SEO), execute local marketing initiatives, measure results with analytics, and drive customer engagement online.

The iAPPS ds platform will enable the customer to easily publish and optimize web content using iAPPS Content Manager, as well as enhance the effectiveness of their web strategies through iAPPS Analyzer. Additionally, what sets the iAPPS ds platform apart from other web engagement solutions is its unique scalability. Despite the high-volume of websites deployed, iAPPS ds effortlessly enables secure brand control and messaging at a corporate level while simultaneously allowing individual administrators the ability to personalize web content to market to their local communities.

This new iAPPS ds customer will be equipped with both back- and front-end mobile capabilities. Each of their 300-plus websites will be implemented with Responsive Design capabilities, a mobile-friendly technology approach that detects the size of a visitor’s device viewing screen and triggers content to automatically adjust to fit the screen accordingly and properly render the website. The mobile-friendly platform also allows businesses to contextualize the customer experience by triggering persuasive content based on what device visitors are using to access the customer’s website. Additionally, administrators can edit and publish content on-the-go with a smart phone or tablet in the touch-capable iAPPS Content Manager user interface.

“The endless scalability franchises and large dealer networks attain through iAPPS ds is a key differentiator that separates the solution apart from other web platforms,” said Ty Glasgow, Executive Vice President of Strategic Alliance at Bridgeline Digital. “Even though iAPPS ds is a relatively new offering in the franchise and large dealer marketplace, the adoption rate of nearly 5,000 enterprise websites has been phenomenal. Never before has a web platform been able to simultaneously showcase the power of a national brand and so easily enable marketing to local communities.”

About Bridgeline Digital

Bridgeline Digital (Nasdaq:BLIN), The Digital Engagement Company™, enables its customers to maximize the performance of their mission critical websites, intranets, and online stores. Bridgeline’s iAPPS^® platform deeply integrates Web Content Management, eCommerce, eMarketing, and Web Analytics to help marketers deliver online experiences that attract, engage and convert their customers across all digital channels. Bridgeline provides end-to-end Digital Engagement solutions and boasts an award-winning team of interactive services professionals. Headquartered in Burlington, Mass., with nine additional locations throughout the U.S. and an Asia Pacific headquarters in Bangalore, India, Bridgeline has thousands of customers that range from middle market organizations to Fortune 1000 companies. To learn more, please visit www.bridgelinedigital.com or call (800) 603-9936.

CONTACT: Brian Bolton
         Bridgeline Digital, Inc.
         Senior Vice President, Marketing
         781.497.3013
         bbolton@blinedigital.com

(TRIP) Names 10 Of The Quirkiest U.S. Accommodations

Floating B&B, Giant Dog, and Desert Cave Among America’s Most Unique Properties

NEWTON, Mass., July 25, 2013 /PRNewswire/ — TripAdvisor^®, the world’s largest travel site*, today announced 10 quirky  accommodations in the U.S., as chosen by TripAdvisor editors. Travelers seeking a unique lodging experience can hunker down in one of these far-out accommodations, which include a larger-than-life beagle, a historic ferry and a subterranean B&B.

“For travelers who want a truly unique experience on vacation and stories to tell for a lifetime, these funky properties will surely fit the bill,” said Brooke Ferencsik, director of communications at TripAdvisor.

To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/57961-tripadvisor-names-10-quirky-u-s-hotels

Caving Inn: Kokopelli Cave Bed and Breakfast, Farmington, New Mexico
Located 70 feet below the ground near the Four Corners region of the U.S., this one guestroom bed and breakfast offers more than the average digs. Travelers are invited to experience the 1,650 square foot dwelling that boasts Southwestern style furniture and decor, a full kitchen, washer/dryer, and even a relaxing flagstone hot tub. “This was a once in a lifetime experience! The cave is comfortable and has many homey touches,” commented a TripAdvisor traveler.

Variety Show: El Cosmico, Marfa, Texas
Located in the southwest region of the Lone Star state, this 18-acre property gives travelers the option to stay in a trailer, tent or teepee. Restored trailers are complete with marine-varnished birch interiors, an eclectic collection of furniture and comfortable amenities including fans, heaters, refrigerators, and cooking supplies. A TripAdvisor traveler noted, “Two nights were not nearly enough – El Cosmico is such a charming funky place, comfortable and staffed with friendly people who want to help you have a great stay.”

Ferry Tale: Yankee Ferry, Red Hook, New York
Floating on the Hudson River in the Red Hook area of Brooklyn, this 1907 steel-hulled passenger vessel invites travelers to climb aboard and rest their heads in its spacious quarters. Guests can check out the boat’s “Polka Dot Garden” that boasts a variety of veggies while enjoying magnificent views of Manhattan. “This is by far the most unique and amazing place I have ever stayed. It is unlike anything else, blending adventure, history, and a sense of home all in one,” said a TripAdvisor traveler.

Ruffing it: Dog Bark Park Inn, Cottonwood, Idaho
Travelers visiting this bed and breakfast located 200 miles north of Boise will be glad to be in the doghouse. Guests are warmly welcomed as they enter the B&B built in the shape of a giant beagle, affectionately named “Sweet Willy,” and make their way to the loft room located in the pooch’s head. Amenities include complimentary breakfast, air conditioning, and as a pet-friendly property, lots of tail-wagging fun. “Simply put this is the best place we’ve ever stayed. A noble and absurd undertaking – made with love and care – Sweet Willy was fun, silly and cozy,” said a TripAdvisor traveler.

Lighthouse Living: East Brother Light Station, Point Richmond, California
Situated on a strait between San Francisco and San Pablo Bay, this Victorian lighthouse offers a romantic, one of a kind stay. Following a 10-minute ferry ride, travelers will immerse themselves in the stunning scenery and lavish guest rooms, and relish the exquisite, fresh fare. “It’s amazing that folks pass this hidden treasure on a daily basis and have no idea of the prospect of relaxation and solitude that awaits,” commented a TripAdvisor traveler.

Back to School: McMenamins Kennedy School, Portland, Oregon
Travelers will get a lesson in some old-fashioned fun at this converted schoolhouse. Fifty-seven former classrooms, still adorned with chalkboards, now house plush beds for guests to rest to their heads. Those interested in extracurricular activities can view a movie in the former auditorium or sip a beverage at the “Detention Bar.” A TripAdvisor traveler commented, “Beyond comparison, this hotel transformed from a former school, had all of the imagined charm and then some.”

Nature Nook: Starlight Llama Bed and Breakfast, Florence, Massachusetts
Twenty miles north of Springfield in western Massachusetts, travelers can connect with nature while enjoying an off-the-grid experience. Running on solar power and recognized in the TripAdvisor GreenLeaders™ program, guests at this bed and breakfast are invited to socialize with the property’s animals including emus, peacocks, and of course, llamas. “I really enjoyed my stay here, the rooms were clean and cozy, breakfast was delicious, and the animals were pretty awesome,” commented a TripAdvisor traveler.

Train Spotting: Red Caboose Getaway, Sequim, Washington
Located at the picturesque junction of the Olympic Mountains and the Dungeness River, this locomotive lodging offers spectacular scenery atop of tracks. Travelers can climb aboard six themed caboose cars refurbished with modern amenities including mini refrigerators, hot tubs, and a collection of train-travel movies, and later enjoy a gourmet meal at the “Silver Eagle” zephyr dining car. “The decor is charming, thoughtful, railroad-authentic, playful and well appointed,” commented a TripAdvisor traveler.

Houseboat Haven: Green Turtle Floating Bed and Breakfast, Boston, Massachusetts
Moored in Boston Harbor, this floating houseboat offers travelers a comfortable rest on the water. After a day of touring nearby sites along the Freedom Trail, guests can enjoy stunning views of the Boston skyline or unwind with luxurious amenities in one of two suites that offer private bathrooms, in-room kitchenettes, and Wi-Fi. A TripAdvisor traveler commented, “It was the best night’s sleep I’ve had in months, and I felt so at ease in the comfort of this wonderful bed and breakfast.”

Masterpiece Hotel: 21c Museum Hotel Bentonville, Bentonville, Arkansas
Located 200 miles northwest of Little Rock, this boutique hotel features its own museum for true art aficionados. Travelers will marvel at the rotating collection of contemporary exhibitions and dynamic installations, and will be equally inspired by the lodging’s gracious guest rooms designed by renowned architect Deborah Berke. A TripAdvisor traveler said, “Prepare to be surprised and delighted by this intriguing hotel and museum. From check-in to check-out, no detail was too small to escape the wonderful staff.”

About TripAdvisor
TripAdvisor^® is the world’s largest travel site*, enabling travelers to plan and have the perfect trip. TripAdvisor offers trusted advice from real travelers and a wide variety of travel choices and planning features with seamless links to booking tools. TripAdvisor branded sites make up the largest travel community in the world, with more than 230 million unique monthly visitors**, and more than 100 million reviews and opinions covering more than 2.7 million accommodations, restaurants and attractions. The sites operate in 30 countries worldwide, including China under daodao.com. TripAdvisor also includes TripAdvisor for Business, a dedicated division that provides the tourism industry access to millions of monthly TripAdvisor visitors.

TripAdvisor, Inc. (NASDAQ: TRIP) manages and operates websites under 20 other travel media brands: www.airfarewatchdog.com, www.bookingbuddy.com, www.cruisecritic.com, www.everytrail.com, www.familyvacationcritic.com, www.flipkey.com, www.gateguru.com, www.holidaylettings.co.uk, www.holidaywatchdog.com, www.independenttraveler.com, www.jetsetter.com, www.niumba.com,  www.onetime.com, www.seatguru.com, www.smartertravel.com, www.tingo.com, www.travelpod.com, www.virtualtourist.com, www.whereivebeen.com, and www.kuxun.cn.

(ETRM) PMA App for VBLOC Therapy in Obesity FDA Review and Filing

EnteroMedics Announces PMA Application for VBLOC Therapy in Obesity Accepted for Review and Filing by FDA

(MDSO) Reports Record Second Quarter 2013 Results

Medidata Solutions (NASDAQ: MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced its financial results for the second quarter 2013 and provided detailed financial guidance.

“Our great execution and the growing market opportunity for the Medidata Clinical Cloud are evident in our record second quarter financial results, growing product penetration and positive outlook for the remainder of the year,” said Tarek Sherif, Medidata’s chairman and chief executive officer. “The strength of our vertical SaaS model comes from the combination of our modern cloud technology and deep domain expertise. Coupled with the industry’s richest repository of clinical trial data, Medidata’s platform is transforming clinical research.”

Second Quarter 2013 Results

• Total revenues for the second quarter of 2013 were $68.1 million, an increase of $14.6 million, or 27%, compared with $53.5 million in 2012. Application services revenue was $56.3 million, an increase of 36% compared with the same period last year.
• GAAP operating income for the quarter increased to $8.8 million, up 55%, compared with $5.7 million a year ago. Non-GAAP operating income* for the second quarter of 2013 increased to $17.5 million, up 60%, compared with $11.0 million a year ago.
• GAAP net income for the second quarter of 2013 was $5.1 million, or $0.19 per diluted share, up 42%, compared with $3.6 million, or $0.14 per diluted share, in the second quarter of 2012. Adjusted non-GAAP net income* for the second quarter of 2013 was $9.5 million, or $0.36 per diluted share, up 63%, compared with $5.8 million, or $0.23 per diluted share, in the second quarter of 2012.
• Application services backlog for the remainder of the year as of June 30, 2013, increased to $110 million, up 38% over the comparable period a year ago. Non-Rave products account for 23% of remaining backlog.
• Total cash, cash equivalents and marketable securities were $140.4 million at the end of the second quarter, an increase of $26.5 million, or 23%, as compared with $113.9 million at the end of the second quarter 2012.
• Cash flow from operations was a record $26.2 million in the second quarter, up 361% year-over-year.

Additional Highlights

• Medidata’s customer base grew to 363 in the second quarter of 2013, up 15% from the second quarter of 2012.
• 45% of customers have committed to multiple products at the end of the second quarter of 2013 as compared with 41% at the end of the first quarter of 2013.
• Non-Rave revenues increased 144% year-over-year, driven by significant growth in Medidata’s patient randomization and trial supply, and medical coding applications.
• Medidata’s revenue retention rate for the quarter was 99.4%.
• Medidata announced the availability of the Medidata Clinical Cloud Study, an easy-to-acquire, ready-in-weeks offering for mid-sized and small customers, single programs and large customer pilots.

“Our revised revenue and profitability guidance continues to validate our prudent investments in sustainable growth,” said Cory Douglas, chief financial officer. “Record operating cash flow this quarter also demonstrates the long-term cash generation potential of Medidata’s highly scalable and vertically focused cloud business.”

Financial Outlook

For the full year 2013, the company now expects:

• Revenues between $273.0 and $276.0 million.
• Professional services revenues in the high $40 million range.
• Non-GAAP operating income between $64.0 and $67.0 million. Based on current estimates, this would equate to GAAP operating income between $29.0 and $32.0 million.
• Adjusted non-GAAP net income, which includes the tax affected impact primarily from stock-based compensation and amortization at a 40% effective tax rate, between $34.0 and $37.0 million. Based on current estimates, this would equate to GAAP net income between $17.5 and $20.5 million.
• While changes in the stock price could change the fully diluted share count, the company is assuming 26.8 million fully diluted shares.

For the third quarter of 2013, the company expects:

• Revenues between $69.5 and $71.0 million.
• Non-GAAP operating income between $16.0 and $17.0 million. Based on current estimates, this would equate to GAAP operating income between $7.0 and $8.0 million.
• Adjusted non-GAAP net income, which includes the tax affected impact primarily from stock-based compensation and amortization at a 40% effective tax rate, between $8.0 and $9.0 million. Based on current estimates, this would equate to GAAP net income between $3.5 and $4.5 million.
• While changes in the stock price could change the fully diluted share count, the company is assuming 27.0 million fully diluted shares.

Conference Call

The company plans to host its investor conference call today at 8:00 a.m. Eastern. The investor conference call will be available via live webcast on the “Investor” section of Medidata’s web site at http://investor.mdsol.com. To participate by telephone, domestic participants may dial 877-303-2528 and international participants may dial 847-829-0023. Those interested in participating in the conference call should dial in at least 10 minutes prior to the call to register. Participants can also join the call via a simultaneous live audio webcast, which will be made available on the “Investor” section of Medidata’s web site at http://investor.mdsol.com. A replay of the conference call can be accessed until Thursday, August 8, 2013, by dialing 800-585-8367 domestically or 404-537-3406 internationally, with the passcode 17553261. An archive of the call will also be hosted on the “Investor” section of Medidata’s web site, http://investor.mdsol.com, for a limited period of time.

About Medidata Solutions

Medidata Solutions is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. The Medidata Clinical Cloud™ brings new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting. We are committed to advancing the competitive and scientific goals of global customers, which include over 90% of the top 25 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations.

Cautionary Statement

Certain statements made in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties about Medidata Solutions, Inc. (“Medidata”), including but not limited to statements about Medidata’s forecast of financial performance, products and services, business model, strategy and growth opportunities, and competitive position. Such statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in these statements. In particular, the risks and uncertainties include, among other things, risks associated with possible fluctuations in our financial and operating results; errors, interruptions or delays in our service or our Web hosting; the financial impact of any future acquisitions; our ability to continue to release, and gain customer acceptance of, new and improved versions of our products; changes in our sales and implementation cycles; competition; our ability to retain and expand our customer base or increase new business from those customers; our ability to hire, retain and motivate our employees and manage our growth; regulatory developments; litigation; and general developments in the economy. For additional disclosure regarding these and other risks faced by the company, see disclosures contained in Medidata’s public filings with the Securities and Exchange Commission including, the “Risk Factors” section of Medidata’s Annual Report on Form 10-K for the year ended December 31, 2012. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. The forward-looking statements are made as of the date hereof, and Medidata undertakes no obligation to update such statements as a result of new information.

*Non-GAAP Financial Information

Medidata provides Non-GAAP operating income, net income and net income per share applicable to common stockholders data as additional information for its operating results. These measures are not in accordance with, or an alternative for, generally accepted accounting principles and may be different from Non-GAAP measures used by other companies. Non-GAAP operating income excludes the impact of depreciation, amortization of intangible assets associated with acquisitions, stock-based compensation expense, and an adjustment to the fair value of contingent consideration. Non-GAAP net income excludes the impact of amortization of intangible assets associated with acquisitions, stock-based compensation expense, and an adjustment to the fair value of contingent consideration. Adjusted non-GAAP net income excludes the impact of tax-affected amortization of intangible assets associated with acquisitions, stock-based compensation expense, and an adjustment to the fair value of contingent consideration. Management uses these Non-GAAP measures to evaluate its financial results, develop budgets, manage expenditures, and as an important factor in determining variable compensation. In addition, investors frequently have requested information from management regarding depreciation and amortization and non-cash, share-based compensation charges, and management believes, based on discussions with investors, that these Non-GAAP measures enhance investors’ ability to assess Medidata’s historical and project future financial performance. While management believes these Non-GAAP financial measures provide useful supplemental information to investors, there are limitations associated with the use of Non-GAAP financial measures. One limitation of Non-GAAP operating income is that it excludes depreciation and amortization, which represents the periodic costs of certain capitalized tangible and intangible assets used in generating revenues in our business. Medidata compensates for these limitations by using these Non-GAAP financial measures as supplements to GAAP financial measures and by reviewing the reconciliations of the Non-GAAP financial measures to their most comparable GAAP financial measures. Investors are encouraged to review the reconciliations of these Non-GAAP financial measures to the comparable GAAP results, which are attached to this press release.

(ALCS) Enters Definitive Agreement to Be Acquired by Argonne Capital

ABILENE, Kan., July 25, 2013 (GLOBE NEWSWIRE) — ALCO Stores, Inc. (Nasdaq:ALCS) (“ALCO” or the “Company”), a general merchandise retailer specializing in providing a superior selection of essential products for everyday life in small-town America, and Argonne Capital Group LLC (“Argonne”), a private investment firm based in Atlanta, Georgia, today announced that the companies have entered into a definitive merger agreement. Under the terms of the merger agreement, Argonne will acquire all of the outstanding shares of ALCO Stores’ common stock for $14.00 per share in cash. This price represents a premium of approximately 63 percent to ALCO’s share price on July 24, 2013, the last trading day prior to ALCO’s announcement of the transaction contemplated by the merger agreement. The cash price for ALCO shares in the proposed transaction totals approximately $47 million.

The independent members of ALCO Stores’ Board of Directors have unanimously approved the merger agreement and recommended that ALCO Stores’ shareholders approve the transaction.

“Argonne Capital is very selective in its acquisition process and focuses on companies that have strong growth potential,” Royce Winsten, Chairman of the Board of ALCO, stated. “We are proud of ALCO’s CEO Rich Wilson and his management team, and how they have positioned the Company for growth. We believe Argonne will help ALCO grow and achieve the goals management and the Board have established for the Company.”

Rich Wilson, Chief Executive Officer, commented: “ALCO Stores has a unique model for providing an attractive merchandise selection and exceptional value to consumers in underserved communities in small-town America. Our associates are supportive of the new brands, variety and value we offer shoppers – as well as the operational improvements behind the scenes. ALCO looks forward to partnering with Argonne, and we believe the support they will provide will accelerate the Company’s plans for sustained growth.”

Argonne Founder and President Michael Klump added, “We are excited about the opportunity to acquire ALCO Stores, which is a strongly-positioned business that has taken the right steps to move the Company forward in today’s highly competitive retail environment. The acquisition of ALCO would be a clear strategic fit within our existing portfolio of companies and real estate investments serving the dining and retail needs of everyday Americans.”

The merger, which is expected to close later this year, is subject to approval from ALCO’s shareholders and other customary closing conditions. Under the terms of the merger agreement, the Company may solicit alternative proposals from third parties at least through August 23, 2013. The Company does not anticipate that it will disclose any developments with regard to this solicitation process unless and until the ALCO Board of Directors makes a decision with respect to any potential superior proposal. There is no assurance that this process will result in a superior proposal.

The transaction is being made through one of Argonne’s affiliates.

William Blair & Company, L.L.C. is serving as financial advisor to the Company, and Norton Rose Fulbright and Lathrop & Gage LLP are serving as legal advisors to the Company. Sagent Advisors, LLC is serving as financial advisor to Argonne, and King & Spalding LLP is serving as legal advisor to Argonne.

About ALCO Stores, Inc.

Founded in 1901, ALCO Stores, Inc. is a broad-line retailer, primarily serving small underserved communities across 23 states, which specializes in providing a superior selection of essential products for everyday life in small-town America. The Company has 213 ALCO stores that offer both name brand and private label products of exceptional quality at reasonable prices. ALCO is proud to have continually provided friendly, personal service to its customers for the past 112 years. ALCO has its distribution center in Abilene, Kansas, and is in the process of moving its headquarters from Abilene to suburban Dallas, Texas. To learn more about the Company visit www.ALCOstores.com.

About Argonne Capital Group, LLC

Argonne is a private investment firm founded in 2003 that seeks to acquire and grow companies primarily within the restaurant and retail industries that will benefit from the firm’s capital resources, operational expertise and extensive real estate knowledge and capabilities. Today, Argonne operates or franchises over 775 restaurants under brands such as IHOP, Applebee’s, Krystal and Stevi B’s Pizza. Spanning 14 states, Argonne’s restaurant portfolio employed over 20,000 people and generated in excess of $1 billion in annual system sales in fiscal year 2012. Argonne’s real estate investment platform, RCG Ventures, LLC, owns over 60 shopping center assets across 18 states with a focus on value-add opportunities. For more information about Argonne, visit www.argonnecapital.com.

Forward-looking statements

All of the statements in this release, other than historical facts, are forward-looking statements made in reliance upon the safe harbor of the Private Securities Litigation Reform Act of 1995, including, without limitation, the statements made concerning the Company’s intent to consummate a merger with an affiliate of Argonne. Forward-looking statements can be identified by the inclusion of “will,” “believe,” “intend,” “expect,” “plan,” “project” and similar future-looking terms. You should not rely unduly on these forward-looking statements. These forward-looking statements reflect management’s current views and projections regarding economic conditions, retail industry environments, and Company performance. Forward-looking statements inherently involve risks and uncertainties, and, accordingly, actual results may vary materially. Among others, the following uncertainties and other factors could cause actual results to differ from those set forth in the forward-looking statements: (i) the risk that the merger may not be consummated in a timely manner, if at all; (ii) the risk that the definitive merger agreement may be terminated in circumstances that require the Company to pay Argonne a termination fee of $2.25 million or reimbursement of their expenses of up to $1 million; (iii) risks related to the diversion of management’s attention from the Company’s ongoing business operations; (iv) risks regarding the failure of the relevant Argonne affiliate to obtain the necessary equity and debt financing to complete the merger; (v) the effect of the announcement of the merger on the Company’s business relationships (including, without limitation, customers and suppliers), operating results and business generally; and (vi) risks related to obtaining any consents to the merger. Further risks that could cause actual results to differ materially from those matters expressed in or implied by such forward-looking statements are set forth under “Risk Factors” in the Company’s Form 10-K for the fiscal year ended February 3, 2013, and its subsequent quarterly reports on Form 10-Q. The Company does not undertake, and hereby disclaims, any duty to update these forward-looking statements, although its situation and circumstances may change in the future.

Additional Information and Where to Find It

In connection with the merger, the Company intends to file relevant materials with the Securities and Exchange Commission (the “SEC”), including a preliminary proxy statement on Schedule 14A. Promptly after filing its definitive proxy statement with the SEC, the Company will mail the definitive proxy statement and a proxy card to each stockholder entitled to vote at the special meeting relating to the merger. INVESTORS AND SECURITY HOLDERS OF THE COMPANY ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE MERGER THAT THE COMPANY WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY AND THE MERGER. The definitive proxy statement, the preliminary proxy statement and other relevant materials in connection with the merger (when they become available), and any other documents filed by the Company with the SEC, may be obtained free of charge at the SEC’s website at www.sec.gov. In addition, investors and security holders may obtain free copies of the documents filed with the SEC at the Company’s website, www.alcostoresinc.com, or by requesting them in writing or by telephone from us at ALCO Stores, Inc., Attn: Corporate Secretary, 401 Cottage Street, Abilene, Kansas 67410-2832, (785) 263-3350 ext. 290.

The Company and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the Company’s stockholders with respect to the merger. Information about the Company’s directors and executive officers and their ownership of the Company’s common stock is set forth in the proxy statement for the Company’s 2013 Annual Meeting of Shareholders, which was filed with the SEC on May 10, 2013. Information regarding the identity of the potential participants, and their direct or indirect interests in the merger, by security holdings or otherwise, will be set forth in the proxy statement and other materials to be filed with SEC in connection with the merger.

CONTACT: For more information, contact:
         Wayne S. Peterson
         Senior Vice President - Chief Financial Officer
         785-263-3350 X164
         email: wpeterson@alcostores.com
         or
         Debbie Hagen
         Hagen and Partners
         913-642-6363
         email: dhagen@hagenandpartners.com

(ONTX) Onconova Announces Pricing of Initial Public Offering

Onconova Therapeutics, Inc., today announced the pricing of its initial public offering of 5,166,667 shares of its common stock at a public offering price of $15.00 per share, before underwriting discounts. All of the shares of common stock are being offered by Onconova. In addition, Onconova has granted the underwriters a 30-day option to purchase up to an additional 775,000 shares of common stock at the same price to cover over-allotments, if any. The shares are expected to begin trading on The NASDAQ Global Market on July 25, 2013 under the ticker symbol “ONTX.”

The offering is expected to close on July 30, 2013, subject to customary closing conditions.

Citigroup and Leerink Swann are acting as joint bookrunning managers for the offering. Piper Jaffray and Janney Montgomery Scott are acting as co-managers.

A registration statement relating to the securities being sold in this offering was declared effective by the Securities and Exchange Commission on July 24, 2013. The offering is being made only by means of a prospectus, copies of which may be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, or by email at batprospectusdept@citi.com, or by phone at 1-800-831-9146; or from Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, or by phone at 1-800-808-7525, ext. 4814, or by email at Syndicate@leerink.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Onconova Therapeutics, Inc.

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova’s clinical and pre-clinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. In addition to rigosertib, the Company’s most advanced product candidate, two other candidates are in clinical trials, and several candidates are in pre-clinical stages.

(ADXSD) Advaxis Updates Business Outlook for 2013

Advaxis, Inc. (OTCBB: ADXS and ADXSD) (the “Company”), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced an updated business outlook for 2013, which includes the development of its clinical strategy to advance its lead product candidate, ADXS-HPV, to registrational trials. The Company has also generated additional encouraging data and continues to strengthen its financial position.

Thomas A. Moore, Chairman and Chief Executive Officer of Advaxis, stated, “Earlier in the year, Advaxis stated that it would provide periodic updates to its business outlook and announced two overarching objectives for 2013: one, to advance our lead product candidate, ADXS-HPV, toward a registration development program and, two, to continue to significantly strengthen our financial position. We have outlined the progress the Company has made on these two goals, as well as anticipated 2013 milestone events.”

Anticipated 2013 Milestone Events

• A determination with respect to the Company’s three applications for Orphan Drug Designations with the FDA for ADXS-HPV in three human papillomavirus (HPV)-associated indications: invasive cervical cancer, anal cancer, and head and neck cancer;
• Initiate dialogue with the FDA to discuss ADXS-HPV clinical development plans for the treatment of cervical cancer;
• Complete the elements required to file an Investigational New Drug (IND) application with the FDA for ADXS-PSA for the treatment of prostate cancer in the first half of 2014;
• Advance the canine osteosarcoma study into Phase 2 and expand to additional collaborative academic centers; and
• File an initial listing application for the NASDAQ Capital Market or NYSE AMEX.

2013 Clinical Program Update

• Final 12-month survival data from the Phase 2 cervical cancer trial announced at the 2013 ASCO Annual Meeting in Chicago in June;
• GOG 0265 safety run-in completed and study opened to the GOG group-wide;
• 16 patients enrolled in REALISTIC head and neck cancer trial;
• 3 patients enrolled and dosed in BrUOG 276 anal cancer study; and
• Third dose cohort underway in the canine osteosarcoma study.

Phase 2 Cervical Cancer Program

In June 2013, the Company submitted an Application for Orphan Drug Designation with the FDA Office of Orphan Products Development for ADXS-HPV for the treatment of human papillomavirus (HPV)-associated invasive cervical cancer.

In June 2013, the final 12-month survival and updated safety data from the ongoing Phase 2 study that is being conducted in India in 110 patients with recurrent cervical cancer were presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting. Preliminary efficacy data continue to show apparent prolonged survival, durable complete and partial tumor reductions, as well as stable disease with ADXS-HPV alone or in combination with cisplatin. 41% (45/110) of patients experienced 104 mild-moderate Grade 1-2 adverse events. 2% (2/110) of patients experienced a Grade 3 serious adverse event, compared to a rate of 130% or more in published studies of active chemotherapy regimens in this disease setting.

The Company has made substantial progress in analyzing the Phase 2 data and is planning a study to determine the best dose and dosing regimen to enhance efficacy without compromising the encouraging preliminary safety profile already observed.

In July, the Company’s clinical team met with global thought leaders in cervical cancer and, under their advisement, are developing the regulatory strategy for the Phase 3 registration approval most clinically relevant to the use of ADXS-HPV and how it can best fit among the treatment options for women with cervical cancer.

The Gynecologic Oncology Group (GOG) of the National Cancer Institute (NCI) continues to conduct a single arm Phase 2 study of ADXS-HPV in 67 patients with recurrent/refractory cervical cancer. As of July 2013, 10 patients have been enrolled in the safety run-in portion of the study.

Head and Neck Cancer Program

In June 2013, the Company submitted an Application for Orphan Drug Designation with the FDA Office of Orphan Products Development for ADXS-HPV for the treatment of human papillomavirus (HPV)-associated head and neck cancer.

Cancer Research UK (CRUK) is funding a Phase 1/2 to evaluate the use of ADXS-HPV for the treatment of 27 patients with HPV positive head and neck cancer. This trial is being conducted at the Aintree Hospital at the University of Liverpool, the Royal Marsden Hospital at the University of London, and the Cardiff Hospital at the University of Wales. As of July 2013, 16 patients have been enrolled in the study.

Anal Cancer Program

In June 2013, the Company submitted an Application for Orphan Drug Designation with the FDA Office of Orphan Products Development for ADXS-HPV for the treatment of human papillomavirus (HPV)-associated anal cancer.

The Brown University Oncology Group (BrUOG) is funding and coordinating a Phase 1/2 study of ADXS-HPV in 25 patients with HPV-associated anal cancer. The trial is being conducted at the Rhode Island Hospital and The Miriam Hospital (the main teaching hospitals of The Warren Alpert Medical School of Brown University). As of July 2013, 3 patients have been enrolled in the study. Multiple institutions will collaborate.

Prostate Cancer Program

The Company expects to file an IND with the FDA for ADXS-PSA in the treatment of prostate cancer in the first half of 2014. In June 2011, the Company conducted a pre-IND meeting with the FDA to discuss the CMC, pharmacology, toxicology, and clinical plans for ADXS-PSA. The required toxicology studies have been completed and data analyses are ongoing.

Canine Osteosarcoma Program

The Company recently announced preliminary data from a Phase 1/2 study that is being conducted at the University of Pennsylvania School of Veterinary Medicine evaluating ADXS-cHER2 for the treatment of dogs with osteosarcoma. Canine osteosarcoma is a leading killer of large breed dogs that causes tumors to form on long leg bones. The standard of care (SOC) is immediate limb amputation followed by chemotherapy and sometimes radiation, however, the cancer typically metastasizes to the lungs, causing death in 6-12 months. In this trial, dogs that have undergone SOC for osteosarcoma, and over-express HER-2/neu in their tumors, are treated with ADXS-cHER2.

Updated preliminary data show a significant survival advantage for 9 dogs that received SOC plus ADXS-cHER2 compared to 11 dogs, whose owners elected not to participate in the trial, but who were followed for survival (p=0.04). At this point in the study, 8 of 9 dogs treated with ADXS-cHER2 are alive (mean survival undefined), compared with 5 of 11 dogs in the control group (mean survival 265 days).

Plans are to expand the study into Phase 2 and to open the study to additional collaborative academic centers.

Regulatory Outlook

The Company has assembled and met with an advisory board of key thought leaders in cervical cancer and is in the process of developing the regulatory strategy and Phase 3 clinical protocols necessary to support a request for an FDA meeting to discuss the clinical development plan for ADXS-HPV.

The Company is compiling the elements required to file an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for ADXS-PSA for the treatment of prostate cancer in the first half of 2014.

Corporate Development Update

In July 2013, David Sidransky, MD, was appointed to the Board of Directors of the Company. Dr. Sidransky has a very strong background in both the business and science of oncology, with a specialty in head and neck cancer. Dr. Sidransky is the Director of the Head and Neck Cancer Research Division and Professor of Oncology, Otolaryngology, Genetics, and Pathology at Johns Hopkins University School of Medicine and has served on the board of directors and as an employee of numerous biotechnology companies.

Business Development Outlook

Advaxis has entered into several confidentiality agreements with biopharmaceutical companies for the license of ADXS-HPV in the U.S., Asia, and India. So far, these discussions have resulted in one memorandum of understanding and a proposed non-binding term sheet with major regional pharmaceutical companies for Asia and India. These preliminary terms establish the commercial parameters of a potential licensing deal. The Company plans to pursue these negotiations to closure in the coming months.

Advaxis has also entered into a confidentiality agreement with the animal health division of a major pharmaceutical company for the license of ADXS-cHER2. The Company plans to pursue discussions with the goal of entering into a licensing agreement. Discussions with other companies are ongoing.

Corporate Outlook

At the annual meeting of stockholders in June, stockholders approved the effect of a reverse stock split and a decrease in authorized shares of the Company at the discretion of the Board of Directors. In July, Advaxis executed the reverse stock split at a ratio of 1-for-125 and decreased the number of authorized shares from 1,000,000,000 to 25,000,000.

The Company intends to seek an uplisting to a national exchange in the near term. We have explained in our recent SEC filings why uplisting to a national market is important to our overall business strategy and financial viability. The Company strongly believes that the combination of completing the reverse stock split and the contemplated uplisting could heighten the interest of the financial community in Advaxis, as well as potentially broaden the pool of investors that may consider investing in the Company, while strengthening its financial health.

About Advaxis, Inc.

Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein(s) that is designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself.

ADXS-HPV is currently being evaluated in four clinical trials for human papillomavirus (HPV)-associated cancers: recurrent/refractory cervical cancer (India), locally advanced cervical cancer (GOG/NCI U.S. study, Clinical Trials.gov Identifier NCT01266460), head & neck cancer (CRUK study, Clinical Trials.gov Identifier NCT01598792), and anal cancer (BrUOG study, Clinical Trials.gov Identifier NCT01671488). Advaxis has over 15 distinct immunotherapies in various stages of development, developed directly by Advaxis and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.

For more information please visit: www.advaxis.com

Forward-Looking Statements

This news release contains forward-looking statements, including, but not limited to: statements as to the anticipated timing of clinical studies and other business developments, statements as to the development of new constructs, expectations as to the adequacy of our cash balances to support our operations for specified periods of time and as to the nature and level of cash expenditures, expectations as to market opportunities, our ability to take advantage of those opportunities, and the risk factors set forth from time to time in Advaxis’ SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2012, which is available at www.sec.gov. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

(FFIV) Announces Third Quarter 2013 Results

F5 Networks, Inc. (NASDAQ: FFIV) today announced revenue of $370.3 million for the third quarter of fiscal 2013, up 6 percent from $350.2 million in the prior quarter and 5 percent from $352.6 million in the third quarter of fiscal 2012.

GAAP net income for the third quarter was $68.2 million ($0.86 per diluted share) compared to $63.4 million ($0.80 per diluted share) in the second quarter of 2013 and $72.3 million ($0.91 per diluted share) in the third quarter a year ago.

Excluding the impact of stock-based compensation and amortization of purchased intangible assets, non-GAAP net income for the third quarter was $88.4 million ($1.12 per diluted share), compared to $84.7 million ($1.07 per diluted share) in the prior quarter and $90.6 million ($1.14 per diluted share) in the third quarter of fiscal 2012.

A reconciliation of GAAP net income to non-GAAP net income is included on the attached Consolidated Statements of Operations.

“Results for the third quarter exceeded our expectations,” said John McAdam, F5 president and chief executive officer. “Strong sales in the Americas led to a 6 percent sequential increase in both product and overall revenue.

“Product sales during the quarter were driven by growing demand for our BIG-IP 4000 appliances and our new entry-level BIG-IP 2000 series. In late June, we released our new midrange BIG-IP 5000 and BIG-IP 7000 series appliances, and initial customer response has been very encouraging.

“The significant performance and scalability enhancements of the new appliances have helped drive growing sales of our security software, including our new Advanced Firewall Manager and our recently upgraded Application Security Manager and Access Policy Manager. Sales of our other software modules have also grown, and demand for our software-only virtual edition products has increased steadily. Along with major enhancements to TMOS, designed to strengthen our SDN integration and cloud scaling capabilities, we recently introduced new 5-gigabit versions of our virtual edition products which run on all major hypervisors including AWS,” McAdam said.

Positive customer response to the company’s new products has contributed to a strong and growing sales pipeline. In spite of ongoing weakness in the global economy, McAdam said he believes that demand for the new products in combination with other business drivers could be a significant catalyst for continued growth.

For the fourth quarter of fiscal 2013, ending September 30, the company has set a revenue target of $378 million to $388 million and a GAAP earnings target of $0.93 to $0.96 per diluted share. Management’s GAAP earnings target includes an anticipated charge of $2.5 million related to a loss on a facility sublease. Excluding this charge, as well as stock-based compensation expense and amortization of purchased intangible assets, the company’s non-GAAP earnings target is $1.17 to $1.20 per diluted share. A reconciliation of the company’s expected GAAP and non-GAAP earnings is provided in the following table:

About F5 Networks

F5 Networks (NASDAQ: FFIV) makes the connected world run better. F5 helps organizations meet the demands and embrace the opportunities that come with the relentless growth of voice, data, and video traffic, mobile workers, and applications—in the data center, the network, and the cloud. The world’s largest businesses, service providers, government entities, and consumer brands rely on F5’s intelligent services framework to deliver and protect their applications and services while ensuring people stay connected. Learn more at www.f5.com.

You can also follow @f5networks on Twitter or visit us on Facebook for more information about F5, its partners, and technology. For a complete listing of F5 community sites, please visit www.f5.com/news-press-events/web-media/community.html.

Forward Looking Statements

Statements in this press release concerning the continuing strength of F5’s business, sequential growth, the target revenue and earnings range, share amount and share price assumptions, demand for application delivery networking and storage virtualization products and other statements that are not historical facts are forward-looking statements. Such forward-looking statements involve risks and uncertainties, as well as assumptions and other factors that, if they do not fully materialize or prove correct, could cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to: customer acceptance of our new traffic management, security, application delivery, WAN optimization and storage virtualization offerings; the timely development, introduction and acceptance of additional new products and features by F5 or its competitors; competitive pricing pressures; increased sales discounts; uncertain global economic conditions which may result in reduced customer demand for our products and services and changes in customer payment patterns; F5’s ability to sustain, develop and effectively utilize distribution relationships; F5’s ability to attract, train and retain qualified product development, marketing, sales, professional services and customer support personnel; F5’s ability to expand in international markets; the unpredictability of F5’s sales cycle; the share repurchase program; future prices of F5’s common stock; and other risks and uncertainties described more fully in our documents filed with or furnished to the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available as of the date hereof and qualified in their entirety by this cautionary statement. F5 assumes no obligation to revise or update these forward-looking statements.

GAAP to non-GAAP Reconciliation

F5’s management evaluates and makes operating decisions using various operating measures. These measures are generally based on the revenues of its products, services operations and certain costs of those operations, such as cost of revenues, research and development, sales and marketing and general and administrative expenses. One such measure is net income excluding stock-based compensation, amortization of purchased intangible assets and acquisition-related charges, net of taxes, which is a non-GAAP financial measure under Section 101 of Regulation G under the Securities Exchange Act of 1934, as amended. This measure consists of GAAP net income excluding, as applicable, stock-based compensation, amortization of purchased intangible assets and acquisition-related charges. This measure of non-GAAP net income is adjusted by the amount of additional taxes or tax benefit that the company would accrue if it used non-GAAP results instead of GAAP results to calculate the company’s tax liability. Stock-based compensation is a non-cash expense that F5 has accounted for since July 1, 2005 in accordance with the fair value recognition provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718 Compensation—Stock Compensation (“FASB ASC Topic 718”). Amortization of intangible assets is a non-cash expense. Investors should note that the use of intangible assets contribute to revenues earned during the periods presented and will contribute to revenues in future periods. Acquisition-related expenses consist of professional services fees incurred in connection with acquisitions.

The reconciliation of the company’s expected GAAP and non-GAAP fourth quarter earnings also excludes an anticipated loss on a facility sublease from net income (non-GAAP). This loss will be incurred during the quarter ending September 30, 2013 in connection with the extension of certain subleases at the company’s corporate headquarters.

Management believes that non-GAAP net income per share provides useful supplemental information to management and investors regarding the performance of the company’s core business operations and facilitates comparisons to the company’s historical operating results. Although F5’s management finds this non-GAAP measure to be useful in evaluating the performance of the core business, management’s reliance on this measure is limited because items excluded from such measures could have a material effect on F5’s earnings and earnings per share calculated in accordance with GAAP. Therefore, F5’s management will use its non-GAAP earnings and earnings per share measures, in conjunction with GAAP earnings and earnings per share measures, to address these limitations when evaluating the performance of the company’s core business. Investors should consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures in accordance with GAAP.

F5 believes that presenting its non-GAAP measure of earnings and earnings per share provides investors with an additional tool for evaluating the performance of the company’s core business and which management uses in its own evaluation of the company’s performance. Investors are encouraged to look at GAAP results as the best measure of financial performance. However, while the GAAP results are more complete, the company provides investors this supplemental measure since, with reconciliation to GAAP, it may provide additional insight into the company’s operational performance and financial results.

For reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure, please see the section in our Condensed Consolidated Statement of Operations entitled “GAAP to Non-GAAP Reconciliation.”